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Abstract 
Measurement of serum AFP level has been widely used as the diagnostic 
test for hepatocellular carcinoma (HCC). Whereas serum AFP level higher 
than 500 ng/ml is almost diagnosed of HCC, modestly raised level can also 
be de t^ected in patients _ benign liver diseases. Therefore, the specificity 
of the test is limited when the AFP level lies In the "grey area" (i.e. 10 - 500 
‘ • . ^ / ‘ ‘ ‘ ‘ ‘ • “ ‘ ‘ ‘ ‘ ‘ 
ng/ml). Recently, in order to differentiate HCC from benign liver disease, lEF 
has been used to separate the AFP isoforms. Presence of monosialo-AFP 
(msAFP) in patient serum is shown to be highly specific to HCC. However, 
the mechanism for the formation of msAFP in HCC is poorly understood. The 
aim of this study was to investigate the mechanism for the formation of 
msAFP in HCC. 
The first set of experiments was performed to Investigate the origin of 
msAFP detected in the HCC patient sera. The in vitro experiment using Hep 
G2 cell culture showed that the presence of msAFP in the culture medium 
was not likeiy due to the extracellular conversion of disialo-AFP to msAFR 
Unforunately, analysis of the tissue and serological AFP isoforms showed 
different banding patterns, leading to impossible comparison between the 
AFP isoforms. Despite of the inconclusive result from the in vivo experiment, 
the in vitro experiment has suggested that msAFP is formed inside the HCC 
cells, and then secreted into the blood stream or culture medium. 
The intracellular mechanism for the formation of msAFP was further 
investigated by studying the serum total AFP, serum msAFP percentage, 
ST2,6Ga} 1 activities and mRNA levels in paired tumor and non-tumor tissues 
from 19 HCC patients. Results showed that 1) serum msAFP percentage 
i 
was positively correlated with the serum AFP levels; 2) the absolute activity 
and percentage change (relative to non-tumor tissue) of ST2，6Gal I in tumor 
tissue were significantly lowered in the patients with increased serum msAFP 
percentage; 3) the percentage change of ST2，6Gal 丨 activity was negatively 
correlated with the percentage of msAFP; 4) the decrease of ST2,6Gal I 
activity in the tumor was not associated with a decrease of ST2,6Gal I 
mRNA level. Therefore both increase production of AFP and decrease in 
ST2,6Gal 1 activity in the tumor tissue are the two possible causes for the 
formation of msAFR In contrast to normal liver tissue, ST2,6Gal 1 activities in 
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Hepatocellular carcinoma (HCC) refers to the malignant tumor of the liver and 
hepatic malignancies include primary and secondary tumors. HCC is the fourth 
most common cancer^ and the most common primary carcinoma^ in the world. 
Globally, the annua丨 incidence is estimated as 530,000 cases�. The incidence 
of HCC in Hong Kong is 47 /100,000 and prognosis is poor^. 
Sex and age 
HCC is more common in males than in females regardless of geography^®, 
although the ratio of incidence between the two sexes vary among regions. 
Generally speaking, the higher the incidence, the higher the maleiemale ratic/， 
which may be attributed to hormonal and genetic factors^ ^ 
In general, the incidence of HCC increases with age, with a tendency to level off 
at older ages '^^ . However, in countries of high incidence, a shift of peak age 
towards the younger population is observed. In most countries, the peak age is 
around 60, but in Mozambique, a country with high HCC incidence, the peak 
age is less than 30 .^ 
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Geographical Distribution 
The geographic distribution of HCC in the world is peculiar. In particular, HCC is 
prevalent in China, Southeast Asia，and subSaharan Africa '^®. It has been 
suggested that the incidence of HCC varies widely from less than 1 in 100,000 
in parts of Northern Europe, to over 100 in 100,000 in parts of Southern Africa 
and China®. Other study reviewed that the age-standardized incidence rates 
vary from 3 per 100,000 in North American men to 80 per 100,000 in Chinal 
Risk factors for Hepatocellular Carcinoma 
Such variation is presumably attributable to the difference in prevalence of 
various etiologic factors. These include chronic viral hepatitis types B and C, 
aflatoxin exposure, alcohol-induced liver disease such as cirrhosis and some 
minor risk factors such as tobacco smoking®-^ ®. 
Chronic hepatitis B and C 
Evidenced by several epidemiological studies and laboratory investigations, 
chronic hepatitis B”-?�and。搬^ are recognized as the major factors which 
Increase the risk of HCC. The risk is greater In the presence of coinfection with 
hepatitis B virus (HBV) and hepatitis C virus (HCV)^°. Chronic infection with 
HBV alone may cause as much as 80 % of Hec”,i2 and the incidence of HCC 
in individuals with chronie hepatitis B is as high as 0.46 % per year'"^ '''®. On the 
other hand, 'm areas with an tntermediate risk for HCC, such as Europe and 
2 
Japan, antibody to tlie hepatitis virus C or the viral RNA being detected in the 
serum of as many as 83 % of HCC pattents^^. 
Cirrhosis 
The annual risk of developing HCC in cirrhosis is between 1 % and 6 0/^ 1^5-16,26-35 
The incidence of associated cirrhosis is also high, being over 80 % in most 
studies3’36，37 However, the role of cirrhosis in HCC Is still unclear. Cirrhosis is 
neither a pre-requisite nor an inevitable consequence of HCC development. 
Hence, liver cell damage and regeneration may be the crucial oncogenic event, 
promoting selection and clonal expansion of transformed cells. 
Dietary Aflatoxin 
Aflatoxins are mycotoxins produced by Aspergillus flavus, a ubiquitous fungus 
contaminating many staple foodstuffs in tropical and subtropical regions^®. A 
positive correlation between exposure to aflatoxins and the incidence of HCC 
has been shown in different epidemiologic correlation studies^ '^^ ®. Each of them 
Indicates that incidence of HCC rises with the increase of aflatoxin in the diet 
Alcohol 
Alcohol does not have known mutagenic properties and cannot be considered 
as a promoting agent for HCC. Nevertheless, in alcohol-associated HCC, the 
effect is observed to be dose dependent. Cirrhosis, with or without other 
etiologic factors such as HBV and HCV, is associated with^  the disease. 
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Mortality from liver cancer 
In consistence to most clinical studies, the mortality / incidence ratio reported by 
the cancer registries is close to 1. Majority of cases did not survive longer than 1 
year^^. Even patients with small tumors after treatment with resection or ethanol 
injection have a significant mortality of at least 50 % in 5 years恥 The high 
mortality rate of HCC is due to the fact that patients with HCC are often unaware 
of its presence until the tumor has reached an advanced Some of 
the underlying reasons for the unawareness are: none of the early clinical 
manifestations of HCC (if present) are pathognomonic; the liver is relatively 
inaccessible to the examining hand, and its large volume allows the tumor to 
reach a large size before it can be felt or before invading adjacent structures^. 
Because of these limitations, a number of serological tumor markers have been 




Treatment for HCC 
At present, surgical resection and liver transplantation are the most effective 
forms of treatment available. However, as mentioned before, the chance of 
curative treatment is often limited by the poor prognosis of the HCC. HCCs 
usually reach a large size before they give rise to symptoms and this makes the 
patients more difficult for curative treatment 
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Tumor markers 
The serological tumor markers that have been tested for diagnosis of liver 
cancer include novel y-glutamyl transpeptidase isoenzyme*�’ variant alkaline 
phosphatase^^, plasma nitrite/nitrate concentrations'*'^ , alpha-L-fucosidase"^^, 
cles-gamma-carboxyprotjirombin46 47 and serum alpha-fetoprotein ( A F P ) 仪 气 




The Alpha-fetoprotein (AFP) gene Is situated on the long arm of chromosome 4 
(4q11-q13)5o. AFP is a glycoprotein which has been reported to consist of 591 
amino acids and one asparaglnes-linked bi-antennary complex-type sugar 丨 
I' 
I 
chain5i>52 jhe molecular weight of AFP is 69 kDa^ .^ The carbohydrate moiety 3 
] 
of AFP has been shown to be microheterogenous by isoelectric focusing "^^ ^® 
and lectin electrophoretic^ -^®^ techniques. The basic structures of the 
oligosaccharide of AFP, purified from the ascitic fluid of a patient with HCC^ ® 
and the hepatoblastoma eel! line Hep is shown to consist of a single N-
linked sugar chain of the bi-antennary complex-type with a degree of 
heterogeneity based on different degrees of terminal slalylation and proximal 
fucosylation (Figure 1). 
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FIGURE 1 一 The structure of the fully sialylated and fucosylated biantennaiy | 
'I 
oligosaccharide reported as the N-linked carbohydrate in alpha-fetoprotein 丨; 
i 
derived from human hepatoma cells. 
i 
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Physiological Functions of AFP 
AFP is normally expressed in the fetal liver, yolk sac and intestine®®"® .^ AFP is a 
major protein component of mammalian fetal plasma and serves as the 
predominant binding protein in the fetus®''"^The serum AFP levels peak at 
approximately 14 weeks of gestation and then decrease, usually reaching 
normal levels (< 10 n g / m l严珏’郎 by 6 months of age® .^ At this point, albumin, 
synthesized mostly in hepatocytes, becomes one of the major plasma proteins. 
Because of the structural similarity with albumin, AFP has been postulated to 
serve the same osmotic and carrier protein functions in the fetus as albumin 
does in the adult Therefore, serum AFP is almost undetectable in a normal 
nonpregnant adulP. 
Re-expression of AFP in adult 
In mammalian adult, re-expression of AFP is found to be associated with rapid 
cell growth, such as liver regeneration after damage, and with certain tumors. 
Wang et a! has suggested that AFP should be considered as a possible direct or 
indirect factor associated with the regulation of growth differentiation, 
regeneration, and transformation In both ontogenetic and oncogenic growth 
processes® .^ However, the precise cellular function of this oncofetal protein in 
mammals has remained an enigma. 
, 7 
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Re-expression of AFP in HCC 
Elevation of serum AFP level is frequently seen in patients with certain benign 
liver abnormalities such as cirrhosis, chronic active hepatitis C, as well as 
malignant HCC'^ ®'®'^ "®^ '®®"^ - Association of AFP to cancer was first reported In the 
micl-1960s. This tumor-associated fetal protein has demonstrated its clinical 
utility as tumor marker48’6i紙68-70 八 serum concentration greater than 500 ng/ml 
is almost diagnostic of HCC, whereas modestly raised level (10 - 500 ng/ml) 
can be detected in both HCC and chronic liver diseases®^®®. In a study 
investigating the expression of the AFP gene in HCC samples, it has shown by 
in situ hybridization that AFP was expressed in the majority of HCC cells?�. 
Isoforms of AFP 
Since about 80 % of patients with HCC have AFP levels above the reference 
range which is less than 1 0 ng/ml"^8’54力5, differentiation between HCC and 
chronic liver diseases is important for early detection of HCC so that effective 
treatment can be performed. Recently, isoelectric focusing (lEF) has been used 
to separate isoforms of AFP and different isoforms were found The lEF 
technique separates proteins based on their pi values. Hence, isoforms of the 
same protein with different charges can be focused at different positions for 
identification. The three major AFP bands separated by lEF are designated as 
band +1, band +11 and band + 川（Figure 2). As identified by electrospray 
ionization-mass spectrometry (ESI-MS) and sialidase digestion experiments, 
these three isoforms of AFP differ by the number of terminal sialic acid residues 
8 
on the carbohydrate side chain. The sialic acid is attached to the carbohydrate 
chain by forming an a2,6 glycosidic bond with galactose residue. Bands +1, +11 
and +111 AFP correspond to disialo-, monosialo- and asialo- AFP respectively^^. 
Specific AFP isoform in HCC 
Investigation with serum AFP from patients with benign liver disease and HCC 
revealed that Band +11 AFP appears to be highly specific for HCC, whereas 
Band +1 AFP usually occurs alone in sera of HCC patients with benign liver 
d i s e a s e 乳 7 ^ 7 3 These findings suggest that detection of Band +11 AFP in the 
blood may allow early detection of HCC in high-risk patients. To improve the 
use of this HCC specific Band +11 AFP as a diagnostic marker for HCC, a 
quantitative assay for monosialo-AFP (msAFP) was constructed by using 
isoelectric focusing and densitometry (unpublished data). With the new assay, 
the diagnostic value of the msAFP level and percentage relative to the total 
serum AFP (total AFP) in 163 HCC patients and 51 patients with liver cirrhosis 
(LC) alone was evaluated. The serum msAFP levels and the msAFP 
percentages of the HCC patients were found to be significantly higher than 
those of the LC patients. Analysis of receiver operation characteristic (ROC) 
curves showed that the msAFP level and the msAFP percentage were valuable 
tumor markers comparable to the conventional total AFP level for discrimination 
of HCC from LC. Both the msAFP level and the msAFP percentage were found 
to be useful in cases where the total AFP level was non-diagnostic (50 - 500 
ng/ml). Based on the analysis of the ROC curves, 31.5 ng/ml of and 19.0 % 
were chosen as the cut-off values of the msAFP level and the msAFP %， 
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Z — ^pp +|jjg asialylated AFP isoforms 
^ ^ / J 
AFP +lle 
AFP +lld 
+ N • • • • 一 " — — A F P +I!C )>• monoialylated AFP isoforms 
AFP +!lb 
+ I AFP 4-113 J 
S^_ — " AFP +lc ， 
— A F P +ib y disialylated AFP isoforms  
AFP +!a ^ 
FIGURE 2 — AFP isoforms as separated by isoelectric focusing (lEF). The three 
major AFP bands separated by 丨EF are designated as band +1，band +11 and 
band +111，which are corresponded to disialylated, monosialylated and 
aslalylated AFP respectively. 
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respectively, for positive diagnosis of HCC to achieve a specificity of 98 %, 
Sialic acid 
Sialic acid is 9-carbon monosaccharide believed to play important roles in a 
variety of biological processes，including the maintenance of serum glycoprotein 
in the clrculation '^^ "^^ and the regulation of certain aspects of cellular 
differentiation"-82 has been shown that sialylation of molecules and cells is 
involved in adjusting the half-life in blood circulation, binding of molecules, cell 
to eel! recognition, cellular migration, aggregation, contact inhibition, malignant 
t r a n s f o r m a t i o n 盼 8 4 and oncogenic transformation® '^® .^ The expression of cell-
surface sialoglycoconjugates is regulated by a family of specific 
sialyltransferases®7—89 
Slaiyltransferase 
Sialyltransferases form a family of 20 or more enzymes which mediate the 
transfer of sialic acid from its nucleotide derivative cytldine monophosphate N-
acetylneuraminic acid to the terminal portion of the oligosaccharide moiety of 
sialoglycoproteins. The enzymes may be distinguished on the bases of the 
carbohydrate chain they use as acceptor and of the type of linkage they form 
with the sub-terminal monosaccharide residue. The different mammalian 
sialyltransferases identified are able to transfer sialic acid to form a2-3, a2-4 
and a2-6 linkages to galactose, a2-6 linkages to N-acetylgalactosamine and a2-
8 linkages to other sialic acid 
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Gaipi，4GlcNAc a2，&sialy丨transferase 
CMP-NeuAc: Gala1,4GlcNAc a2，6 sialyltransferase (ST2,6Ga! 1) [EC 2.4.99.1] 
is one of these enzymes and mediates the transfer of silaic acid to Galp1-
4GlcNAc termini of complex type, N-linked oligosaccharides^^"^'^'^. This is, in 
fact, the only sialyltransferase identified so far which Is capable of adding sialic 
acid in the a2,6 llnkage^^. 
Characterization of ST2，6Gdl I 
ST2,6Gal I The gene of ST2,6Gal I is localized to human chromosome 3 (q21-
q28)95. The nucleic acid sequence of the enzyme predicts a 46.7 KDa 
polypeptide composed of a short amino terminal cytosolic region and a single 
trans-membrane region, foHowed by a carboxyl terminal catalytic region® '^® .^ 
ST2,6Gal I is found to be localized predominantly within the Golgi apparatus 
and trans-Golgi network of cell cytoplasm®^'''°\ where it takes part in the post-
translational modification of newly synthesized secretory and cell surface 
glycoproteins 郎'99 
Expression of ST2，6Gal I 
In both rat and human, ST2,6Gal I is expressed by many tissues but at a 
dramatically different expression level 102,103 jj^g enzyme has been shown to be 
existing at particularly high levels in the liver— but remains at a low level in 
other tissues like colon and intestine. At molecular level, tissue-specific 
12 
expression of ST2’6Gal 丨 transcripts has been examined in a variety of 
t i s s u e s卿0 6 Regulation of ST2,6Gal I in these tissues is mainly at the 
transcriptional level through the use of different cell-specific promoters which 
generate transcripts differing in their 5'-untranslated regions^^^. 
The three major mRNA species identified in human are Y+Z form, X form and 
hepatic formio? (Figure 3). The Y+Z form was formerly cloned from a placenta 
cDNA nbraryio8 and it contains the S'-untranslated exons Y and Z. This form has 
been detected in several tissues other than placenta and Is suggested to 
represent the basal or housekeeping expression of the gene® .^ The X form 
harbours the S'-untranslated exon X instead of exons Y and Z彻 and this form 
has been detected in B-lymphocytIc cells in a stage of differentiation^^® and 
colon cell lines'^Lastly, the hepatic form lacks exons Y, Z and X but contains a 
short specific sequence in front of the exon I. This form was initially identified in 
hepatoblastoma Hep G2 ceil line and later in human liver. Transcription of the 3 
isoforms starts from different points In the ST2,6Gal I gene and is driven by 
different promoters. Different mechanisms involved allows the cell to modulate 
the transcription of ST2’6Ga丨！ in response to different stimuli in a cell-specific 
manner 
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Y Z I 11 III IV V VI 
Y+Xform 
X I II iii IV V VI 
I I h i m ^ r 遍 i I 
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I !i III IV V VI 
I I Im I g I "1 
Hepatic form 
FIGURE 3 _ Schematic representation of ST2，6Gal 丨 mRNA transcripts. The 3 
forms share exons I 一 VI but varies in the presence of 5'untranslated exons Y 
and Z (top) or X (middle) or the liver-specific sequence (bottom). Shaded area 
represents the protein-coding region ( Dall'Olio, F et ai, 1999). 
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General Features of ST2,6Gal I Activity 
During fetal development, the ST2’6Gal 丨 activity is progressively increased in 
fetal liver and yolk In mammalian adult, different levels of tissue-specific 
ST2,6Gal I mRNA expression appear to be correlated with different levels of 
this enzyme activity in t i s s u e s ' ' O n the other hand, clinical'''''''''''^ and 
experimental^风 studies have suggested a relationship between high levels of 
ST2，6Gal I activity with a more malignant phenotype. 
Relationship Between AFP Isoforms and ST2,6Gai! in Fetal Mouse Model 
It has been demonstrated by Ernst F. et at in fetal mouse that sialyltransferase 
is responsible for the regulation of AFP microheterogenity during 
developmentiG5. in the study, the components of mouse fetal plasma AFP 
during gestation were analysed. It has been observed that the plasma non-
siaiylated and monosialylated AFP decreased continuously until undetectable 
after an increase in the beginning. Conversely, the disialylated AFP increased 
continuously throughout the period. Correlating with this, the sialyltransferase 
activity in the mouse feta! liver during the same period was also studied. Results 
reviewed that the increase in the enzyme activity in liver is virtually identical with 
the proportion of disialylated AFP in plasma. These indicated that the increase 
in sialyltransferase in liver correlates well with the increased sialylation of 
plasma AFP. Moreover, Grimes has demonstrated in normal 3T3 mouse 
fibroblast cells that the decrease in sialyltransferase was responsible for the 
decreased sialic acid content of transformed cells '^'®. However, the relationship 
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between sialyltransferase and siaiyiation in human liver cancer is still poorly 
understood. 
Change In ST2,6Gal I Activity in Transgenic Mouse Models of HCC 
Studies of ST2，6Gal I activity in HCC has been conducted in several animal 
models. To study the glycosylatlon changes in mouse HCC, transgenic mice 
expressing the region of T/t antigen of the SV40 genome under the control of 
the promoter region of the human ATIII genes were created by Pousset et a\ to 
develop HCC''^ ^. As screened by lectin-ELISA, the siaiyiation of glycoproteins 
secreted into serum and in liver membrane from normal and tumour-bearing 
mice was compared. Siaiyiation by ST2,6Gal I was found to be increased while 
siaiyiation by other sialyltransferases were not. Moreover, the expression of 
ST2,6Gal I mRNA in the transgenic mice was also found to be increased and 
was suggested to be responsible for the increase in enzyme activity. However, 
direct study using human HCC specimen has not been performed. 
Study of Activity of ST2,6Gal I in Colon Carcinoma 
Unlike the case in HCC, the alteration of ST2,6GaI in colon carcinoma has been 
studied extensively in cell lines, animals and human. Colon cancer cells 
commonly express the Y+Z for transcript, however, transcription of the liver form 
may be switched on in addition in certain colon cell lines''''®. It has been reported 
that the activity of ST2,6Gal I Is increased compared with the surrounding 
normal mucosa in about 90 % of human colon cancer specimens but to 
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markedly different degrees among patients''''^. This up-regulation of ST2,6Gal I 
is suggested to cause an increased sialylation of cancer cell membranes, as 
revealed by the binding with the SNA lectin^s in other in vitro experiments, it 
was found that regulation of ST2,6Gal I activity was not necessarily at the 
transcription level— 
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Objective of the Project 
Using isoelectric focusing (lEF) to separate the isoforms of serum AFP based 
on their different pi values, the three major bands, designated as Bands +1, +11 
and +111, were identified. Among the bands, Band +1 is found to be 
predominating in patients with chronic liver diseases, whereas Band +il is 
observed to be present specifically in patients with HCC. Band +!, +11 and +!n 
were later shown to consist of disialo-, monosialo- and asialo-AFP respectively, 
by electrospray ionization-mass spectrometry (ESl-MS) and sialidase digestion 
experiments The cause(s) for the appearance of serum monosialo-AFP (msAFP) 
in HCC patients remain(s) unknown. 
The formation of msAFP in addition to disialo-AFP (dsAFP) in HCC cases can 
be due to either incomplete sialylation of the AFP, or due to conversion of 
dsAFP to msAFP. In the former case, the incomplete sialylation may be due to 
saturation of ST2,6Gal I enzyme as a consequence of over-production of AFP, 
and/or decrease of cellular ST2，6Gal I activity, whereas in the latter case, the 
conversation of dsAFP to msAFP may be an extracellular event, and may be 
caused by removal of sialic residue(s) from dsAFP by sialidase / glycosidase 
digestion after the molecule has been synthesized and secreted out of the cell. 
Although the relationship between ST2,6Gal I and HCC has been examined in 
several animal models, direct studies on human tissues have not been reported, 
As suggested by the fetal mouse model that sialylation of AFP is regulated by 
the ST2，6 Gal I activity, we hypothesize that the presence of msAFP in HCC 
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may, or at least in part, be related to a decrease in the ST2，6Gal 丨 activity in the 
tumor cells. Since we cannot exclude the possibility that the presence of msAFP 
is due to other reasons, as mentioned above, the objectives of this project were: 
1. To investigate whether the presence of msAFP in serum of HCC 
patients is formed Intracellularly or as a consequence of extracellular 
conversion of dsAFP to msAFP; 
2. To investigate whether the presence of msAFP is a consequence of 
an increased production of AFP; 
3. To investigate whether the presence of msAFP is a consequence of a 
decreased ST2,6Gal ！ activity in HCC tissue; 
4. To investigate whether the change of ST2，6Gal I activity in HCC is 
regulated at the transcriptional level. 
In order to answer whether the presence of msAFP in serum of HCC patients 
was due to an extracellular event, a preiiminary ceil line experiment was done. 
In this experiment, the percentage of Band +11 AFP among the AFP molecules 
secreted into the culture medium was examined to see if the percentage was 
increased with time after prolonged incubation at 37 °C in the short-term 
cultured medium. Results obtained from this in vitro experiment was then 
confirmed with the in vivo experiment by comparing the AFP isoforms within the 
liver tissues and those present in the sera. 
To answer whether presence of msAFP is a consequence of over-production of 
AFP, the relationship between the msAFP percentages and the serum AFP 
level was investigated. 
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To examine whether the the presence of msAFP is a consequence of a 
decreased ST2,6Gal I activity in HCC tissue, the ST2，6Gal I activity of the tumor 
and non-tumor tissue from patients with histologically confirmed primary HCC 
were measured by means of a lectin assay and compared. The relationship 
between the enzyme activity and the percentage of msAFP in serum would then 
be evaluated. 
Finally, in order to investigate if the tumor ST2,6Gal I activity is regulated at the 
transcriptional level，the ST2，6Gal I mRNA level was semi-quantified by RT-
PGR ELISA assay. The relationship between the mRNA level and the enzyme 
activity could then be examined. 
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Chapter 1 Formation of Monosialylated AFP inside Hepatoma 
Cells 
1.1 Introduction 
Alpha-fetoprotein (AFP), which is normally expressed In the fetal liver, yolk sac 
and intestine59’6i’役，\s seen to be re-expressed in adults with HCC and other 
benign liver diseases. lEF has been used to identify different AFP isoforms, 
among which Band +11 AFP (monosiaio-AFP, a hyposialylated form) is highly 
specific to HCC. Previous studies have shown in a fetal mouse model that 
during gestation, ST2,6Ga丨 I activity in liver cells increased together with the 
percentage for the fully sialylated AFP isoform while the percentages of mono-
sialylated and non-sialylated AFP isoforms decreased. 
Since tumor ceils have been suggested to attain the characteristics of fetal cells, 
we hypothesize that the ST2,6Gal I activity in HCC cells is decreased, leading to 
the formation of hyposialylated AFP. However, the formation of hyposialylated 
AFP could happen inside hepatoma cells due to inefficient transfer of sialic acid, 
or outside the cells due to the removal of sialic acids on AFP, or both. Hence in 
order to understand the mechanisms involved in the formation of msAFP, we 
must first find out whether formation of msAFP happens inside or outside the 
cells. In the present study, five hepatic cell lines were first evaluated for the 
possibility of being as cell line models. After evaluation, the appropriate cell lines 
were used to study if the msAFP was converted from dsAFP in the culture 
medium. In order to investigate if the formation of the secreted msAFP molecule 
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takes place inside the liver cells in vivo, the IEF banding pattern of cellular AFP 
in non-tumor and tumor tissue was then examined and compared. 
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1.2 Materials and methods 
1.2.1 Materials 
1.2.1.1 Cell lines 
The hepatoblastoma Hep G2 cell line, the hepatocellular carcinoma Hep3B cell 
line and the adenocarcinoma SKHep 1 cell line，were commercially available 
from ATCC. Hep 305 and PLC/5 were in house hepatocellular carcinoma cell 
lines. 
1.2.1.2 Tumor and Non-tumor Tissues from HCC Patients 
Paired tumor and non-tumor tissues were collected from 19 HCC patients during 
surgical removal of the tumor mass. The clinical features of the 19 patients are 
summarized in Table I. All cases were histologically confirmed with HCC. 
Patients were numbered according to their serological AFP levels. Among the 
19 patients, 3 were female and 16 were men. The age range of the patients was 
31 to 75. The serological AFP levels of 10 cases were below 500 ng/ml and 9 
were above 500 ng/ml. 
1.2.1.3 Other Materials 
Cells were grown in D-MEM medium obtained from GIBCO BRL Life 
Technologies, USA, or medium kindly provided by Dr Nathalie Wong, 
Department of Clinical Oncology, Faculty of Medicine, The Chinese University of 
Hong Kong. Penicillin-Streptomycin was purchased from GIBCO BRL Life 
Technologies, USA. Protease inhibitor (Pefabloc® SC PLUS) was purchased 
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Case Sex Age Differentiation Cirrhosis AFP (ng/ml) 
1 F 51 moderate yes 20 
2 M 75 moderate yes 25 
3 M 52 welt to moderate no 64 
4 M 44 well yes 69 
5 M 44 moderate to poor yes 73 
6 M 53 moderate to poor yes 100 
7 M 65 moderate yes 150 
8 F 41 well yes 151 
9 M 57 poor yes 152 
10 M 46 moderate yes 365 
11 M 60 moderate to poor yes 618 
12 M 67 moderate yes 1057 
13 M 48 moderate no 1427 
14 M 43 moderate no 1500 
15 F 31 well to moderate yes 2726 
16 M 40 moderate no 3338 
17 M 35 moderate to poor no 5505 
18 m 42 poor yes 12185 
19 M 72 poor no 42837 
TABLE I 一 Clinical features of the patients histologically confirmed with HCC 
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from Roche Diagnositc, Boehringer Mannheim, Germany. Bovine serum 
albumin (BSA) was purchased from Sigma Chemical Company (Sigma, St. 
Louis, MO, USA). Anti-human AFP and horseradish peroxidase conjugated anti-
human AFP anitbodies were purchased from DAKO，Glostrup, Denmark. AFP 
standard was purchased from DAKO, Denmark, horseradish peroxidase 
conjugated polyclonal rabbit anti-AFP (DAKO, Denmark), ABTS and BM Blue 
were purchased from Roche Diagnostic, Boehringer Mannheim, Germany. 
Enhanced chemiluminescence ECL kit and the Hyperfilm-ECL were purchased 
from Amersham International PLC (Amersham, Pharmacia Biotech, UK). 
1.2.2 Methods 
1.2.2.1 Cell Culture 
Hep G2, SKHepI, Hep 3B and PLC/5 cells were grown in D-MEM medium 
(GIBCO BRL Life Technologies, Gaithersberg, MD, USA), Hep 305 cell was 
grown in Hep 305 medium. All culture medium was supplemented with 0.01 % 
Penicillin-Streptomycin (GIBCO BRL Life Technologies, Gaithersberg, MD, USA) 
and 10 % fetal bovine serum in a humidified 37 incubator with 5 % CO2. For 
sub-cu!turing, confluent cultures were harvested by brief trypsinization (0.05 % 
trypsin, 0,53 mM EDTA), and the split ratio was 1:10. 
12.2.2 Extracellular AFP Preparation 
Cells were seeded in 75 cm^ culture flasks and experiments were performed 
after achieving 50 % confluence. The cells were washed 2 times with PBS and 
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then 7 ml of HBSS (without FBS) was added to the flask followed by incubation 
in humidified 3 7 � C incubator with 5 % COsfor 2 hours. HBSS without FBS was 
used to eliminate the interference of any bovine AFP present in FBS which 
would otherwise affect the results. After incubation, the medium was collected 
and stored at -20 °C until extracellular AFP analysis. The cells were harvested 
and the number of cells was counted using a hemocytometer and recorded. The 
cells were then saved for intracellular AFP quantitation. 
1.2.2.3 In&acellular AFP Preparation 
The whole cell extract was used for AFP analysis. All steps were carried out at 
4 � C . The cells were homogenized on ice in 1 ml of sodium phosphate buffer 
(10 mM NaP04, 150 mM NaCI, pH 7.4), containing 0.8 mM protease inhibitor 
(Pefabloc® SC PLUS, Roche Diagnositc, Boehringer Mannheim, Germany), with 
a Polytron-Aggregate (Kinetica, Switzerland) using a 11 mm cutting probe at a 
speed setting of 5 for 16 seconds. After centrifugation at 4 ''C for 10 minutes at 
1000 rpm, the supernatant fraction was centrifuged again at 13 000 rpm for 30 
minutes at 4 °C. The supernatant was then collected and stored at -20 °C for 
AFP analysis. 
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1.2.2.4 Cellular Preparation of Tissue Samples 
Tissue Processing 
The tissues were cut into small pieces, snap frozen with liquid nitrogen after 
receipt, and stored at 一 7 0 � C until used. Sera from those patients, which were 
collected before the operation, were stored at — 2 0 � �u n t i l further analysis. 
Cellular Preparation of Tissue Samples 
The frozen tissues (0,3 -1 g) were homogenized on ice in 1.5 ml of phosphate 
buffered saline (PBS, AMRESCO, USA). The procedures were same as those 
for intracellular preparation for cell lines in section 1.2.2.3. 
1.2.2.5 Coomassie Dye-Binding Protein Assay (Bradford Assay) 
A dilution series of bovine serum albumin (BSA, Sigma, USA), ranging from 
0 一 1 mg/ml, in PBS containing 0.05 % Tween 20, 0.025 % BSA, pH 7.4，was 
prepared as the calibration standards. The assay was carried out in a microtiter 
plate format Two-hundred microlitres of Coomassie Brilliant Blue (CBB) solution 
(0,01 % CBB G-250, 4.75 % ethanol, 8,5 % phosphoric acid) was added to each 
well, and the absorbance was measured with a microplate reader at 595 nm and 
recorded as background. Ten microlitres of standard or sample with appropriate 
dilution was pipetted into each well and mixed. The plate was then shaken 
gently at room temperature for 5 - 10 minutes. The absorbance of each well 
was measured at 595 nm. After background subtraction, the final readings of the 
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standards were used to generate a standard curve, and the concentrations of 
the samples were calculated. 
1.2.2.6 AFP Quantitation by ELISA 
The AFP levels in the samples were quantified with a sandwich-type enzyme 
linked immunosorbent assay (ELISA). Firstly, the antibody (anti-AFP) was 
coated to wells to capture the AFP molecules present in the samples. The 
captured antigens were then detected by peroxidase conjugated anti-AFP 
antibodies. 
The 96-well plate was coated with 100 |i! polyclonal rabbit anti-AFP (1:200， 
DAKO, Denmark) in coating buffer (0.2M sodium bicarbonate buffer, pH9.6) and 
incubated overnight at 4 or 2 hours at 37�C. After the removal of the coating 
solution, the wells were washed once with 200 ju! diluting buffer (PBS containing 
0.05% Tween 20, 0.25 % BSA, pH7.4). The non-specific binding sites in the 
wells were then blocked by incubating with 200 jliJ diluting buffer for 1 hour at 
room temperature. Following the removal of the diluting buffer, 26 …of 
standards (DAKO, Denmark) of various concentrations or samples diluted with 
the diluting buffer, were added to the wells in duplicate and incubated at 37 
for 1 hour. After washing the wells 3 times with 200 jul washing buffer (PBS 
containing 0.5 % Tween 20, pH 7.4), 100 \x\ horseradish peroxidase conjugated 
polyclonal rabbit anti-AFP (1:3000, DAKO, Denmark) In diluting buffer was then 
added to each well and incubated at 37 for 30 minutes. The wells were then 
washed with 200 ‘ul washing buffer for 5 times followed by the addition of 
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substrate. For measurement of AFP concentration higher than 10 ng/ml, 100 fil 
ABTS {Roche Diagnostic, Boehringer Mannheim, Germany) was used as 
substrate and the plate was incubated at room temperature for 20 minutes with 
gentle shaking. The absorbance in each well was then determined with 
microplate reader at 406 nm. For measurements with AFP level expected to be 
lower than 10 ng/ml, 60 of BM Blue (Roche Diagnostic, Boehringer Mannheim, 
Germany) was used as substrate. After incubation for 20 minutes at room 
temperature with shaking, 120 1M H2SO4 was then added to each well. The 
absorbance in each well was then determined at 450 nm with reference 
wavelength of 690 nm. 
12.2.7 Isoelectric Focusing 一 Immunoblotting 
}EF and Western Blotting 
The PhastGel Dry lEF 4 - 6.5 was swelled In 1400 ^！ of a solution containing 5 
M urea and ampholytes (6.25 % Pharmalyte pH 4.5 - 5.4, Amersham 
Pharmacia Biotech, UK) for 45 minutes at room temperature. Samples were 
diluted with 2 % AFP negative human serum to 10 ng/ml. lEF was performed 
using the PhastSystem at a constant temperature of 10 °C. The Initial pre-
focusing step was carried out at 2000 V for 75 Vh. Then samples, 1ul per lane, 
were applied directly to the gel surface and allowed to penetrate into the gel for 
15 Vh at 200 V. The final focusing step was carried out at 2000 V for 450 Vh. 
The focused proteins were transferred to nitrocellulose membrane using the 
PhastTransfer (Amersham Pharmacia Biotech, UK), which was carried out at 20 
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V for 5 Vh at 15�C, in the presence of transfer buffer (25 mM Tris-base, 193 
mM glycine). 
Immunodetection 
The nitrocellulose membrane was soaked in milk solution (2 % milk in Tris-
buffered saline: 46.25 mM Tris-HCI, 3.75 mM Tris-Base, 150 mM NaC! ,pH 7.2) 
for 1 hour at room temperature to block the non-specific binding sites. The 
blocked membrane was then incubated with 15 ml polyclonal rabbit anti-human 
AFP (1:200, DAKO, Denmark) in the milk solution at room temperature for 90 
minutes. After washing, the membrane was incubated in 15 ml horseradish 
peroxidase conjugated anti-rabbit immunoglobulin (1:500, DAKO, Denmark) in 
the milk solution overnight at 4�C. Following washing, the AFP protein bands 
were visualized using the enhanced chemiluminescence ECL kit (Amersham 
Pharmacia Biotech, UK) and the Hyperfilm-ECL (Amersham Pharmacia Biotech, 
UK). 
1.2.2.8 Semi-Quantification of AFP Isoforms 
The image of each AFP band was scanned with a densitometer (GS-700, Bio-
Rad, California, USA), and the intensity of each band was expressed as a 
percentage of the total intensity of all AFP bands. 
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1.2.2.9 Protein Analysis of AFP in Cell Culture Medium 
SDS - Polvacrvlamide Gel Electrophoresis for AFP in Cell Culture Medium 
Four volumes of appropriately diluted samples was mixed with one volume of 5x 
sample buffer (10 mM Tris-HCI, 5mM EDTA, 12.5 % SDS, 0.05 % bromophenol 
blue, pH 8.0) containing freshly prepared dithiothreitol at a final concentration of 
1 %. The mixture was boiled for 5 minutes to denature the proteins. SDS 
polyacrylamide gel electrophoresis was then carried out on a PhastGei Gradient 
10 -15, using the Phast System. Phast SDS buffer strips were used as buffer 
source for SDS-PAGE. All lanes were loaded with 0.05 ng of AFP. Separation of 
proteins was performed at a constant temperature of 15�C，at 100 V for 65 Vh. 
The separated proteins were transferred to nitrocellulose membrane using the 
PhastTransfer, which was carried out at 20 V for 5 Vh at 15 °C, in the presence 
of transfer buffer (25 mM Tris-base, 193 mM glycine, 20% methanol). 
immunodetection 
The immunodetection steps for SDS-PAGE were similar to that for lEF analysis, 
as detailed in section 1.2.2.8’ with a few modifications as follows. Only one 
antibody, horseradish peroxidase conjugated anti-human AFP (1:200, DAKO, 
Denmark), instead of the two antibodies, anti-human AFP and horseradish 
peroxidase conjugated anti-rabbit immunoglobulin, was used. 
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1.2.2.10 Monitoring Conversion of Disialo-AFP to msAFP in Culture 
Medium 
To test if the formation of hyposialyiated AFP was an event happening after fully 
sialylated AFP was secreted from cells, culture medium collected after 
/ 
incubation with cells for 2 hours at 37 were subjected to prolonged incubation 
at 37 and the changes in proportions of the isoforms were monitored. Half of 
the HBSS collected after incubation with cells was stored at -20 ^C. The other 
half was subjected to prolonged incubation at 37 ^C overnight. The next day, 
half of the cullture medium was stored at 一 2 0 � C and half was subjected to 
another incubation at 37 °C for overnight again. Hence, 3 sets of HBSS samples 
were collected: one was HBSS collected immediately after incubating with cells; 
one was subjected to prolonged incubation at 37 ^C overnight (24 hours) after 
incubating with cells; and the last was subjected to prolonged at 37 °C for two 
overnights (48 hours) after incubating with cells. The AFP isoforms in the 3 sets 
of samples were subjected to lEF analysis. 
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1.3 Results 
1.3.1 AFP Obtained from Cell Culture 
To determine if all the hepatoma cell lines produced and secreted AFP, AFP 
levels in both the cell lysates and the short-term cultured mediums of the five 
cell lines were measured and the results are shown In Table 11 and Table ill 
respectively. All cell lines produce AFP, but at different levels. 
1.3-2 iEF for AFP in Cell Culture Medium 
To examine if all the cell lines investigated produced hyposialylated AFP, the 
AFP in the culture medium was subjected to IEF. Results review that only the 
Hep G2 gave an AFP banding pattern, consisting of both Band +1 and Band +11, 
which was similar to that of serum AFP from an HCC patient. The other four cell 
lines gave a similar banding pattern that was different from that of serum AFP 
(Figure 4). 
i.3.3 SDS'PAGE Analysis of AFP 
Figure 5 shows that the AFP produced by Hep G2 has a protein size similar to 
that of AFP in serum. The other four eel! lines produced AFP of a similar size 
but larger than the size of serum AFP. 
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Cell Line Intracellular [AFPj (pg/ug of protein) 
Hep G2 1200.0 + 270.0 
Hep 305 3.73 + 0.3 
SKHepI 5.03 土 0.2 
Hep3B 969+ 15.3 
PLC/5 3.1+0.2 
TABLE II — Iiitmcdliilar AFP levels for different hepatic cell lilies. Intracellular 
AFP was obtained from the whole cell lysate and intiaceliular AFP level was 
measured by ELISA as detailed in Methods. The AFP concentration indicated was 
the mean value of the measurements 土 S.E.M. (i.e. n 二 3). 
34 
Cell Line Extracellular AFP level (fg/celi) 
Hep G2 530.0+ 253.0 
Hep 305 63.2+ 11.9 
SKHepI 14.6 + 3.72 
Hep 3B 475.0 + 33.3 
PLC/5 127 ±16,8 
TABLE III - Extracellular AFP levels for different hepatic cell lines. 
Extracellular AFP was obtained from culture mediimi incubated with cells for 2 
hours at 37 AFP level was measured by ELISA as detailed in Methods. The 
AFP level indicated was the mean value of the measurements 土 S.E.M. (i.e. n 二 3). 
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FIGURE 4 - I E F for extracellular AFP secreted by Hep G2 cell 
line after prolonged incubation at 37 °C. Samples were diluted to 
10 ng/ml with 2 % normal serum and 1 jiil was loaded in each lane. 
Extracellular AFP was obtained by incubating 50 % confluent 
Hep G2 cells with HBSS in 75 cm^ flask for 2 hours at 37 r . The 
procedures for lEF were detailed in Methods. The negative control 
was the fresh HBSS without incubation with Hep G2. Serum AFP 
obtained from a patient histologically confirmed with HCC was 
used as standard. 
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FIGURE 5 - Western blot for the extracellular AFP secreted by 
different hepatic cell lines and the serum AFP obtained from a 
HCC patient. SDS-PAGE was carried out on a PhastGel Gradient 
10-15，using the Phast System. Approximately 20 ng of AFP was 
loaded in each iane.After electrophoresis, the proteins were 
transferred to a nitrocellulose membrane using the PhastTransfer, 
The AFP bands were then bound with the horsemdish peroxidase 
conjugated anti-human AFP antibody and visualized by the 
ECL system. 
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1.3.4 Stability of AFP Isoforms After Secretion into Ceil Culture Medium 
As demonstrated above, among the cell lines investigated, only Hep G2 
produced wild-type AFP with an lEF banding pattern similar to serum AFP in 
HCC patients. Being more reflective to the situation in human, only Hep G2 but 
not the other four cell lines was used for further studies. 
To investigate if the formation of msAFP is an extracellular event happening in 
the culture medium, AFP in short-term cultured medium was subjected to 
prolonged incubation at 37 X and analysed. Figure 6a shows that a similar 
banding pattern, with Band +1 and Band +11 AFP, was attained in the 3 sets of 
HBSS samples, which had or had not been subjected to prolonged incubation at 
37 °C. Densitometric analysis of the two AFP bands also shows consistent 
percentages of the bands among the 3 sets of sample (Figure 6b). These 
results demonstrated that incubation of short-term cultured medium at 3 7 � C did 
not alter the banding pattern nor the percentage of hyposialyiated AFP, hence 
the msAFP found in the culture medium should have formed inside the cells and 
secreted out of the cells. 
1-3-5 Comparison of the AFP Isoforms Between Liver Tissues and Sera 
To determine if the extracellular AFP composed of isoforms similar to those of 
the cellular AFP in vivo, isoforms of cellular AFP from non-tumor and tumor 
tissues were investigated, compared and correlated with those of the serum 
AFP, Two cases with only serological Band +1, and two cases with serological 
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FIGURE 6 一（a) IEF for extracellular AFP secreted by Hep G2 cell 
line after prolonged incubation at STC. Samples were diluted to 10 
Tig/mlwith 2 % normal seruni and 1 jul was loaded m each lane. 
Extracellular AFP was obtained by incubating 50 % confluent Hep 
G2 cells with HBSS in 75 cm^ flask for 2 hours at 37°C After 
incubation, HBSS collected was divided into 3 portions for 
different treatements: stored at -20 until IEF analysis (lane 2), for 
prolonged incubation at overnight (lane 3) and prolonged 
incubation at for 2 overnights (lane 4). The procedures for IEF were 
detailed in Methods. The negative control (lane 1) was the fresh 
HBSS without incubation with Hep G2. Serum AFP obtained from 
a patient histologically confirmed with HCC was used as standard, 
(b) Graphical presentation for the intensities of the AFP bands 
secreted by Hep G2 cell line with or without prolonged incubation. 
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Band +1 and Band +11 AFP were randomly chosen from the samples, their 
corresponding pairs of tissue homogenates were subjected to lEF analysis. 
Figure 7 shows that the cellular and serological AFPs were not focused at the 
same positions, giving different patterns. Hence, the comparisons of AFP 
isoforms between liver tissues and sera could not be made. 
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FIGURE 7 — IEF for AFP in serum，tumor and non-tumor tissues. 
AFPs in each set of samples were AFPs obtained from the same 
patient. “S” represents the serum AFP; “T” represents the AFP 
from tumor tissue; and “NT” represents AFP obtained from non 
tumor tissue. Sets 1 and 2 are samples from the msAPP unchanged 
group and sets 3 and 4 are samples from the msAFP increased 
group. The relative positions for serum Band +1, Band +11 and 
Band+III AFP are indicated. 
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1.4 Discussion 
1.4.1 Origin of the Extracellular msAFP - in vitro Model 
In this part of the project, five hepatic cell lines including Hep G2’ Hep 305, Hep 
3B, SKHepI and PLC/5 were used for setting up cell line models. In evaluation 
of the cell lines, both the extracellular and intracellular AFPs were analysed. 
Among the five cell lines, only Hep G2 produced AFP with an expected banding 
pattern consisting of Band +1 and Band +11 on lEF separation, which is 
consistent to the structural analysis weight obtained by electrospray ionization 
mass spectrometry (ESMS). In the EMSM analysis, it has been shown that the 
AFP isoforms secreted into the culture medium by Hep G2 and those in human 
serum have similar molecular weight, Surprisingly, AFP obtained from 
the other four cell lines had a size larger than that of the wild-type, and showed 
an atypical pattern which were apparently similar among themselves. As only 
Hep G2 produced AFP isoforms, msAFP and dsAFP, similar to those found in 
human serum, only Hep G2 was used to set up a cell line mode! for further 
analysis in setting up a cell line model for this project. 
The Hep G2 cell line was then used to investigate if the presence of msAFP was 
caused by conversion of dsAFP to msAFP by the enzyme(s) in the culture 
medium. This investigation was particularly important to ask if msAFP was 
formed inside the cells and secreted. The lEF banding pattern of the AFP 
remained unchanged upon prolonged incubation in the short-term cultured 
medium. That indicates that glycosidase / sialidase, enzymes which could 
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convert dsAFP to msAFP, were not present inside the culture medium. The 
result, hence, strongly suggests that msAFP is produced in the Hep G2 cells 
and secreted to the culture medium. 
1-4.2 Origin of Circulating msAFP - in vivo Mode! 
Owing to the similarity of the AFP isoforms of Hep G2 cell and serum of HCC 
patients, results obtained in this study with Hep G2 suggest that a similar 
phenomenon may also happen in vivo. In order to directly answer whether 
msAFP was formed in the hepatoma cell, and secreted to blood circulation in 
vivo, the intracellular AFP were extracted, and compared with extracellular AFP 
in terms of 丨EF banding patterns. 
Results showed that the cellular and serological AFPs were not focused at the 
same position and gave different banding patterns as separated by lEF. One of 
the possible reasons accounting for this was significant amount of the extracted 
cellular AFP was still in the mid-way of the production line, which was 
incompletely synthesized or glycosylated. The mixture of AFP containing the 
mature or immature forms of AFP might lead to the change in 丨EF banding 
patterns. Because of the difference in the AFP banding patterns, the cellular and 
serological AFP isoforms could not be compared. 
Since AFP is a secretory protein, it is secreted out of the cells rapidly after 
formation in the liver. This might be another reason explaining why the 
corresponding Bands +l and +11 AFP in serum could not be identified in tissues. 
To overcome this problem, some modifications could be dons to the 
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experiments described in our in vitro model mentioned above to investigate 
whether sialidase / glycosidase is present in serum converting dsAFP to 
msAFP. Serum obtained from HCC patients with AFP removed by 
immunoprecipitation could be added to the culture medium during prolonged 
incubation to see if the percentage of msAFP would increase after incubation. 
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1.5 Conclusion 
Although results from the in vivo model comparing the cellular and serological 
AFP isoforms was not conclusive, the in vitro cell line model suggests that 
hyposialylated AFP isoforms, especially msAFP, are formed inside the 
hepatoma cells, and released to culture medium. Therefore, changes in certain 
Intracellular factors of hepatoma cells should be responsible for the appearance 
of msAFP in HCC patient sera. 
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Chapter 2 Presence of msAFP in the serum HCC Patient is a 
Consequence of Decrease in the Activity of ST2,6Gal I in the HCC Cells 
2.1 Introduction 
In the previous chapter, it is suggested that the msAFP molecules is formed 
inside the HCC cells and then secreted into the culture medium. These findings 
suggest that serological AFP is a reliable marker reflecting those in HCC cells. 
Moreover, they also support our hypothesis that the hyposialylation of AFP in 
HCC patients is caused by the decrease in activity of ST2，6Gal I. 
Sialylation of glycoproteins, ！ike AFP, is mediated by sialyltransferases. 
ST2,6Gal I is one of these enzymes which transfers the sialic acids to Gaipi-
4GlcNAc termini of complex type, N-linked ologosaccharides^^, in the a2’6 
linkage^®. In mammals, ST2,6Ga!丨 is found to be localized predominantly within 
the Golgi apparatus and the trans-Golgi network of cell cytopolasm®?-, where 
it takes part in the post-translational modification of newly synthesizes secretory 
and cell surface g l y c o p r o t e i n s ^ ' ^ 
In human, ST2,6Gal 丨 is expressed by many tissues but at a dramatically 
different level expressionio^ io^ 丁he enzyme has been shown to be existing at 
particularly high levels in the liver®® but remains at a low level in other tissues 
like colon and intestine. ST2，6Gal 丨 has been studied extensively in certain 
cancers such as colon cancer. Regarding HCC, the enzyme has been 
investigated in the In several mouse models, which suggested that ST2,6Gal I 
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activity was increased in HCC cells and the enzyme activity was closely 
associated with the mRNA levels. However, the status of ST2，6Gal in HCC is 
still poorly understood in human. 
To evaluate our hypothesis that formation of msAFP is, at least in part, due to 
the decrease In ST2,6Gal I in HCC cells, ST2，6Gal I activity in human liver 
tissues and its relationship with the sialylation of AFP were studied in this study. 
Serum AFP isoforms of patients were separated by IEF and the amount of 
msAFP was semi-quantified. Since we cannot exclude the possibility that the 
presence of serum msAFP is a consequence of over production of AFP, the 
relationship between the serum msAFP percentage and the serum AFP level 
was first investigated. The relationship between the serum msAFP percentages 
and the activity of tissueST2，6Gal I was then examined to prove our hypothesis. 
Finally, whether the ST2，6Gal I activity in the tumor was regulated at the 
transcriptional level was investigated. 
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2.2 Materials and Methods 
2.2.1 Materials 
2.2.11 Tumor and Non-tumor Tissues from HCC Patients 
The information was described in section 1.2.1.2 
2 . 2 1 2 Other Materials 
Antibodies were purchased from DAKO, Giostrup，Denmark. CNBr-activated 
Sepharose 4B was purchased from Pharmacia, Uppsala, Sweden. Sambucus 
nigra agglutinin (SNA) and asialo-feutin were purchased from Sigma Company 
(Sigma, St. Louis, USA), Rat ST2,6Ga! I was purchased from Sigma Company 
(Sigma, St. Louis, USA). RNeasy Mini Kit was purchased from Qiagen. 1 纽 
strand cDNA Synthesis Kit (AMV) was purchased from Roche Diagnostic, 
Boehringer Mannheim, Germany. Reliant Gel was purchased from FMC 
BioProducts. Reagents for PGR were purchased from Roche Diagnostic, 
Boehringer Mannheim, Germany, unless otherwise specified. Primers were 
obtained from GIBCO BRL Life Technologies. USA. PGR ELISA (DlG-detection) 
kit was purchased from Roche Diagnostic, Mannheim Boehringer, Germany. 
222 Methods 
2.2.2.1 Cellular Preparation of Tissue Samples for AFP Quantlfation 
The procedures for tissue processing and cellular preparation were detailed in 
section 1.2.2.4. 
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2.2.2.2 AFP Quantification by ELISA 
The procedures for AFP assay were detailed in section 1.2.2.6. 
2.2.2.3 AFP Partial Purification 
For serum samples with AFP level lower than 50 ng/ml, AFP is partially purified 
using Blue Sepharose CL-6B before separation by lEF. The principle is to use 
Cibacron Blue 3G-A, which is covalently attached to Sepharose CL-6B, to bind 
and remove kinases, dehydrogenases and most other enzymes containing 
cofactors Including NAD+，NADP+, coagulation factors, interferons, lipoproteins 
and albumin in the serum, leaving AFP partially purified. 
Blue Sepharose CL-6B Gel Preparation 
The required amount of gel was weighed out and swollen in double distilled 
water. The gel slurry was de-gased for 15 minutes, followed by washing 4 times 
with 50 ml double distilled water to remove the additives. This was then washed 
4 times with 50 ml PBS and transferred to a centrifuge tube. After de-gased for 
30 minutes to get rid of the air bubbles, the gel was centrifuged at 3000 x g for 
10 minutes. The supernatant was removed. The swollen gel was resuspended 
in same volume of PBS. One point two milliliters of gel suspension was 
aliquoted into each of the 15 mi tubes, and centrifuged at 400 x g for 10 minutes. 
The supernatant was discarded and 260 of PBS was added to each of the 
tubes. The gel suspension was then ready to use. 
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Partial Purification and Concentration of AFP 
Forty microiitres of the patient serum was added to the gel suspension. The 
mixture was vortex well and incubated at 37 for 90 minutes with mixing every 
15 minutes. Following the incubation, 4 ml of 10 % PBS was added to each tube 
and mixed well. The mixture was then centrifuged at 3000 rpm for 10 minutes. 
The supernatant was saved, and concentrated to about 40 i^l with a Biomax 30 
K centrifuge filter tube. The volume of the AFP concentration of the concentrate 
was measured. The concentrate was supplemented with normal human serum 
at a final concentration of 2 %, and stored at 一 2 0 until further analysis. 
2.2.2.4 Semi-quantitaion of msAFP 
The procedures for semi-quantitative analysis of msAFP were detailed in 
sections 1.2.2.7 and 1.2.2.8. 
2 2.2.5 Microsomal Fraction of Tissue Samples 
The tissue sample lysate was prepared as mentioned in section 1.2.2.4. The 
microsomal pellet obtained after centrlfugation in the last step was resuspended 
in Tris-HCI buffer (15 mM Tris-HCI, pH 6.0) and stored at — 7 0 � C for ST2,6Gal I 
activity assay. 
2.2.2.6 Coomassie dye-Binding Protein Assay (Bradford Assay) 
The procedures for the protein assay were detailed in section 1.2.2.5. 
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2.2.2.7 ST2,6Gdl I Activity Assay 
The ST2，6Gal assay established is based on the specific a2,6-!inkage binding 
property of Sambucus nigra agglutinin (SNA) that preferentially binds sialic acid 
attached to terminal galactose in a2,6, but not 2,3 or 2,8 linkage. SNA was firstly 
coupled to CNBr-activated Sepharose and incubated together with the reaction 
mixture containing ST2，6Gal I，asialofetuin (ASF) and radiolabeled sialic acid 
The microsomal fraction from the tissue sample was used as the source of 
ST2’6Gal I when measuring the enzyme activity in tissue. Instead of the whole 
cell homogenate, the microsomal fraction, was used because ST2，6Gal is 
localized predominantly within the Golgi apparatus and the Golgi networkio各 107 
During incubation at 37 overnight, ST2,6Gal ！ transfers the radiolabeled sialic 
acids to ASF, and the ASF with radiolabeled sialic acid subsequently bound to 
the immobilized SNA. Since SNA specifically recognizes glycoproteins sialylated 
at a2,6-linkage, ASF sialylated by other types of sialyltransferase, which may be 
present, in other linkages are not captured. After washing away all the unbound 
substances, the radioactivity of the radiolabeled ASF binding to the immobilized 
SNA retained is measured. As the amounts of SNA, ASF and sialic acid are in 
excess in the reaction mixture, the amount of radioactive sialic acid transferred 
will be directly proportional to the degree of ST2，6Gal I activity. With reference 
to the standard curve obtained using ST2，6Gal 丨 at various concentrations, the 
ST2,6Gal I activity of the sample tissue can be quantified. 
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Sambucus nigra aqqIutinin-Sepharose preparation 
Sdmbucus nigra agglutinin (SNA) (Sigma, St. Louis, USA) was coupled to 
CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden), approximately 1 
mg/ml, for 2 hours at room temperature in coupling buffer (0.1 M NaHCOs, 0.5 
M NaCI, pH 8.3). Non-specific binding sites were blocked using 0.2 M glycine, 
pH 8.0 overnight at room temperature. Uncoupled substances were removed by 
extensively washing the gei alternately with acetate buffer (0.1 M acetic acid, 
0.5 M NaCI, pH 4.0) and the coupling buffer, pH 8.0. The gel was then washed 
and stored in PBS, pH 7.4 at 4°C until used. 
ST2.6Gal I activity assay 
The tissue microsomal extract was used as source of a2,6-S!aly{transferase and 
asialofetuin (ASF) (Sigma, St. Louis, USA) was used as sialic acid acceptors. 
The ST2,6Gal I activity assay was carried out in a mixture containing 10 j^ g 
tissue microsomal fraction, 15 mM Tris-HCI buffer pH 6.0, 0.1 % BSA, 0.1 % 
Triton X-100, 45 mM NaCI, 125 jig ASF, 125 fiM CMP-sialic acid and 0.25 ]iC\ 
CMP-fH]-sialic acid in a final volume of 20 |il’ The mixture was added to 30ul 
SNA-gel mixed, and incubated at 37 °C overnight. After washing the gels for 4 
times with washing buffer (PBS containing 0.5 % Tween 20)，the SNA bound 
materials were released by vortexing with 300 \x\ 1 M H2SO4 for 30 seconds. 285 
\i\ of the supernatant was transferred to a vial, and 5 ml scintillant solution was 
added. The amount of radiolabeled glycoproteins was then counted in a liquid 
scintillation counter. Commercial rat ST2，6Ga! I (Sigma, St. Louis, USA) was 
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used to prepare the calibration standards. One unit is defined as the enzyme 
activity that transfers 1 fimo! sialic acid at 3 7 � C within 1 minutes from CMP-
sialic acid to ASF in the reaction mixture. 
2.2.2.8 Semi-Quantitative Reverse Transcription - Polymerase Chain 
Reaction - Enzyme Linked Immunosorbent Assay 
Outline of the RT-PCR ELISA method is shown in Figure 8. Total RNA was 
extracted from the tissue sample, and mRNA was reverse transcribed to cDNA. 
The cDNA was used as template for semi-quantitative PGR amplification with 
primers specific for the S丁2’6Gal I or p-actin gene. In each amplification, DIG-
labeled dNTP was used, and only limited cycles were performed. After 
amplification, the amplicons are quantified by ELISA. First, the amplicons were 
denatured and hybridized to a biotinylated probe specific for the S丁2，6Ga丨丨 or p-
actin gene. Next, the amplicons were captured onto an ELISA plate coated with 
avidin, which recognizes biotin. Finally, the captured amplicons were detected 
with an anti-DIG peroxidase conjugate. 
2.2.2.9 RNA Extraction from Frozen Liver Tissue 
Frozen liver tissue of 10 - 30 mg was disrupted and homogenized using a motor 
and pestle (Kontes, Vineland, New Jersey) in a sterile microcentrifuge tube. 
Total RNA was then extracted using the RNeasy Mini Kit (Qiagen) and the 
procedures were done according to the protocol provided by the manufacturer. 
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FIGURE 8 — Outline of the PCR-HLISA method 
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The total RNA was eluted with 30 fxl of RNase free water and the RNA 
concentration was quantitated using GeneQuant (Pharmacia, Uppsala, Sweden) 
by taking absorbance at 260 nm. 
Z2.9.10 Quality Check of Extracted RNA by Agarose Gel 
Electrophoresis 
One volume of gloxal sample buffer (FMC BioProducts) with 0.6 pg of ethidium 
bromide was mixed with 3 ^g of extracted RNA and incubated for 65�C for 15 
minutes for denaturation. The mixture was then chilled on ice for 1 minute. Two 
microliters of 6x loading buffer (Promega，Corporation, Madison, Wl, USA) was 
added to the denatured RNA before loading to the 1.25 % SeaKem® Gold 
agarose gel (Reliant RNA Gel, FMC BioProducts). The electrophoresis was 
carried out for 45 minutes at a constant voltage of 100 volts and the banding 
pattern was visualized by using a transilluminator set at 320nm. The 
appearance of 18S and 28S RNA in samples indicated a satisfactory RNA 
extraction. 
2.2.9.11 First Strand cDNA Synthesis 
Messenger RNA in 1 mg of total RNA was reverse transcribed into single-
stranded cDNA using a strand cDNA Synthesis Kit (AMV) (Roche Diagnostic, 
Boehringer Mannheim, Germany). The o!igo-p(dT)i5 primer provided in the kit 
was used. The cDNA was stored at -80 °C until used. 
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2.2.9.12 Semi-Quantitative Polymerase Chain Reaction (PCR) of ST2，6Gal / 
cDNA 
A 20 ii\ reaction mixture consisting 1x PCR buffer, 2mM DIG-labeled dNTP, 2.5 
m M M g C b , 1 juM o f e a c h primer, 0 .83 U Taq D N A ploymerase, 0.022 fxM 
TaqStart Antibody, 0.8 U uracil glycosylase, 1 jiil of diluted first strand cDNA and 
sterile water was prepared. Primers used were STF1 {5'-
CCTGAACAATTCCAGCCTGCTCCTTT-3') and STR01 (5，-
GACGATGTTTCCAATCCCCTGTACCA-3'), amplifying nt 1160 一 1581 of the 
ST2，6Gal I cDNA. cDNA was diluted with Tris-EDTA buffer (10 mM Tris-HCI, 1 
mM EDTA, pH 8.0) accordingly before PCR amplification. The mixture was 
incubated at room temperature for 10 minutes. After that, an initial denaturation 
step of 2 minutes at 94 °C was done, followed by 25 cycles of 1 minute at 94 
1 minute at 63 primer for annealing, and 1 minute at 72 "C for extension. A 
final extension run of 7 minutes at 7 2 � C was performed to ensure complete 
elongation of all amplicons. Purified cDNA from normal human liver was used as 
positive control. For validation experiment, 40-cycles, instead of 25, PCR was 
performed. The specificity of a PCR was checked by agarose electrophoresis to 
see if the size of the PCR product was the same as the expected value, 421 bp. 
2.2.9.13 Semi-Quantitative Polymerase Chain Reaction (PCR) of p-aotm 
cDNA 
To normalize the ST2,6Gal I mRNA result, p-actin mRNA was quantified, p-actin 
cDNA reversed-transcribed from the extracted mRNA was amplified using 
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primers p-actinF01 (5'-CTTCTACAATGAGCTGCGT-3') and p-actinR01 (5'-
TCATGAGGTAGTCAGTCAG-3') to generate 305 bp ampiicons. The PGR for p-
actin was carried in a similar setting as for ST2,6Gal I with a few modifications 
as follows. The concentration of MgCb used in the reaction mixture was 3.5 mM 
instead of 2.5 mM and the primer annealing temperature in each PGR cycles 
was 60 °C instead of 63 
2.2.9.14 Quality Check of PGR Products by Agarose Gel Electrophoresis 
The quality of PGR products was checked by agarose gel electrophoresis to 
ensure specific amplification. 10 jiil of PGR product was added with 2 of 6x 
loading buffer (Promega Corporation, Madison, Wl, USA) and loaded into a 4 % 
NuSieve® 3:1 Plus agarose (Reliant DNA gel, FMC BioProduct). Electrophoresis 
was carried out under a constant voltage of 100 volts for 45 minutes and band 
patterns were then visualized with a UV transilluminaor at 320 nm. The 
appearance of a single, specific band with expected size implies the quality and 
specificity of the PGR amplification. 
2.2.9.15 ELISA Detection 
Quantitative detection of the DIG-labeled PGR products was done using the 
PGR ELISA (DIG-detection) kit (Roche Diagnostic, Mannheim Boehringer, 
Germany). Five microlitres of PGR product was denatured in 20 jil of 
hybridization buffer in a microcentrifuge tube for 10 minutes at room 
temperature. One hundred microlitres of 7.5 pmol of corresponding biotinylated 
58 
probes was then added to the mixture and vortex. 100 jil of the whole mixture 
was pipetted to the well of a avidin-coated microtiter plate. The sequences of 
the probes used were: PSTR01 (biotin-5'-TGCATTGGGCACAATTGTAA-3') for 
the ST2，6Gal ！ PGR products; and and Pp-actlnROI (bbtin-5，-
GTCCAGACGCAGGATGGCAT"3') for the p-actin. This hybridization step was 
carried out at 55 °C for 3 hours for ST2’6Gal I assay, or 2 hours for p-actin 
assay. The plate was subsequently washed three times with washing buffer. 
The DNA-probe hybrid was determined by incubating with 110 ^I/well anti-D!G-
HRP conjugate at 37 °C for 30 minutes. After washing for five times with 
washing buffer, 100 of substrate, BM Blue, (Roche Diagnostic, Mannheim 
Boehringer, Germany) was pipetted into each well. The reaction was allowed to 
proceed for 20 minutes at room temperature and then stopped by adding 100 jul 
of 1 M H2S04. The optical density of the solution was determined at 450 nm 
(with a reference wavelength of 690 nm). One of the samples with high 
ST2，6Gal I mRNA level was used to prepare the relative calibrators for RT-PCR 
ELISA. The cDNA was obtained by reverse transcription, and diluted to various 
concentrations and subsequently subjected to PCR-ELISA. A 25-fold dilution of 
the reverse transcription product was assigned as 1 arbitrary unit of the mRNA 
levels. 
2.2.2.16 Statistical Analysis 
The Wilcoxon Signed Rank test was used to compare the differences between 
the non-tumor and tumor groups. The Mann-Whitney Rank Sum test was used 
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to compare the differences between the msAFP Increased and unchanged 
groups. Correlations between the markers were analysed by the Spearman 
Rank Order Correlation test The differences and correlations were considered 
as significant when P < 0.05. 
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2.3 Results 
2.3.1 Semi-Quantitation of msAFP 
2.3.1.1 Standard Curve for Semi-Quantitation of Percentage of msAFP 
To semi-quantify the percentage of msAFP, a standard curve was generated 
(Figure 9). It is shown that the relative Band +11 intensity is directly proportional 
to the msAFP % in the calibration standards. Using the calibration curve, the 
msAFP % in the serum samples when the total AFP concentration of a sample 
was equal to or higher than 50 ng/ml can be quantified. Having determined the 
msAFP %, the msAFP concentration can then be calculated from the total AFP 
concentration. 
2.3.1.2 Categorization ofmsAFP Increased and Unchanged Groups 
Typical results of IEF banding patterns for HCC patient serum AFP is shown in 
Figure 10. Our separate study shows that the cut-off value of the msAFP 
percentage for differential diagnosis of HCC from liver cirrhosis is 19 %, giving a 
sensitively of 53 % and a specificity of 98 % (unpublished data). Cases with 
msAFP higher than 19 % were categorized as msAFP increased group and 
those with msAFP lower than 19 % were considered as msAFP unchanged 
group. After categorization, 8 out of 18 cases fell into the msAFP increased 
group and 11 into the msAFP unchanged group (Figure 11). 
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FIGURE 9 - Calibration curve generated by plotting the relative 
Band +11 intensity against the percentages of msAFP. 
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Patient Samples 
• I �！！垂“-得”••丨 
FIGURE 10 — Typical lEF pattern for serological AFP from HCC 
patients. One microlitre of sample diluted to 10 ng/ml of AFP with 
2 % AFP negative human serum was loaded in each lane. EEF was 
performed using the PhastSystem and the bands the bands were 
then transferred to a nitrocellulose membrane. The proteins were 
hybridized with anti-human AFP antibody and subsequently to 
HRP conjugated anti-rabbit immunoglobulin. The AFP bands 
were then visualized using the ECL system. 
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FIGURE 11 — The monosialo-AFP (msAFP) percentage in sera of 
19 HCC 
patients. The msAFP percentage was obtained by 
calibration of the Band +11 AFP intensity, as identified by 
isoelectric focusing (lEF), with a calibration standard curve 
(Figure 9). The 8 patients marked with ‘‘ * “ were patients with 
msAFP percentage higher than 19 % and were classified into the 
msAFP increased group. The remaining 11 patients were patients 
with msAFP percentage lower than 19% and were categorized 
into the msAFP unchanged group. 
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2.3.1,3 Comparison of the AFP Levels between the msAFP Unchanged 
and Increased Groups 
The median AFP level in the msAFP unchanged group was 152.2 ng/ml and 
that in the msAFP increased group was 2076.5 ng/ml (Table 丨V). Comparison of 
the AFP levels between the two groups shows no significant difference (Figure 
12) (P=0.091. Mann-Whitney Rank Sum Test). 
2.3.2 Evaluation of the ST2，6Ga丨丨 Assay 
2.3.2.1 Standard Curve for theSTZ6 Gal / Activity Assay. 
Figure 13 shows the typical standard curve obtained with radioactivity plotted 
against the ST2,6Gal I activity. The radioactivity is directly proportional to 
ST2，6Gal 丨 enzyme activity up to 100 uU. The specificity of the assay was tested 
by setting up a negative control using a2,3-sialyltransferase instead of ST2,6Ga! 
I. No reactivity was found in the negative control. 
2.3.3 Measurements and Comparisons of the Activity of ST2,6Gal I in 
Non-tumor and Tumor Tissues 
2.3.3.1 Comparison between the ST2,6Gal I Activities in Non Tumor and 
Tumor Tissues 
The ST2,6Gal ！ activities in the microsomal fraction of non-tumor and HCC 
specimens of 19 patients is shown in Figure 14 and the data are summarized in 
Table V. The median ST2,6Gal I activities in non-tumor and tumor tissues were 
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Group Serum AFP Concentration (ng/ml) 
Median (25^ 75出 percentile) 
msAFP Unchanged 152.2 (65.8，947.2)  
(n-11)  
~ m s A F P Increased 2076.5 (125.5，8845.0) 
TABLE IV - The median, 25也 and 75伍 percentile of the serum AFP 
concentration in the msAFP unchanged and increased groups from 19 
patients histologically coirfiimed with HCC. 
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FIGURE 12 — Serum AFP concentrations between the msAFP 
unchanged and increased groups. Comparison of the AFP 
concentrations between the two groups showed no significant 
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Figure 13 - Standard curve for the ST2,6Gal 1 assay. A 20 jul of 
reaction mixture containing 10 \xl of sialyltransferase, 4 jil of 
CMP-SA, 4 jul of ASF and 2 jul of ^H-labeled CMP-SA. 30 jul of 
SNA coupled to CNBr-activated Sepharose 4B (1 mg/ml) was 
used to capture the ASF sialylated at the a2,6-linkage. The whole 
mixture was incubated at 37°C overnight and after washing for 3 
times with washing buffer, the radioactivity of the captured Un-
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FIGURE 14 一 Box plot showing the median, and 
percentile of the activity of ST2,6Gal 丨 in non-tumor and 
tumor tissues. The paired tissues were obtained from 19 
HCC patients. 
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Tissue ST2,6Gal I activity (p,U/ug of protein) 
Median (25'\ percentile) 
Non-tumor 94,5 (69.9, 157.6) 
Tumor 96.9 (55.3,156.9) 
TABLE V 一 The m e d i a n， a n d 75出 percentile of the ST2,6Gal I activity in paired 
non-tumor cirrohotic and tumor tissue from 19 patients histologically confirmed 
with HCC. The ST2,6Gal I assay performed was as mentioned in Methods. 
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94.5 ^U/fxg of protein and 96.9 of protein respectively, and were not 
statically significant (P = 0.679, Wiicoxon Signed Rank Test). 
2.3.3.2 Tumor and Non-Tumor ST2,6Gal I Activities Between the msAFP 
Increased and Unchanged Groups 
The ST2,6Gal I activities of the tumor and non-tumor tissues in the msAFP 
increased and unchanged groups are presented in Table VI. To determine if the 
ST2,6Gal I activities in the tumor tissue was decreased when msAFP was 
increased in patient serum, comparisons were made between the msAFP 
increased and unchanged groups. Compared with msAFP unchanged group, 
the ST2,6Gal I activities of the tumor tissue in the msAFP increased group were 
significantly lower (P = 0.035, Mann-Whitney Rank Sum Test), whereas the 
ST2,6Gal I activities of the non-tumor tissue were not significantly different (P = 
0.302) (Figure 15). 
in the msAFP increased group, the median ST2，6Gal I activities of non-tumor 
and tumor tissues were 124.9 iiU^ig of protein and 56.7 /aU/jig of protein 
respectively (Table VI). The ST2,6Gal I activity of the tumor tissue was 
significantly lower (P = 0.039, Wiicoxon Signed Rank Test) (Figure 16). 
Regarding the msAFP unchanged group, the median ST2,6Gal I activites of 
non-tumor and tumor tissues were 89.0 _ f x g of protein and 120.9 of 
protein respectively (Table VI). In contrast to the result in the msAFP increased 
group, a significant increase was found in the ST2,6Gal I activity of the tumor 
tissue comparing to the non-tumor tissue (P = 0.042, Wiicoxon Signed Rank 
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ST2,6GaI I Activity (|iU/fig of protein) 
Median percentile)  
Tissue msAFP Unchanged Group msAFP Increased Group 
( n = l l ) (n = 8)  
Non-Tumor 89.0 (66.56,118.2) 124.9 (71.3,163,1) 
Tumour 120.9 (92 J，204.0) 5 6 . 7 ( 4 5 . 4 , 9 1 . 2 ) “ 
TABLE VI - The median, 25也 and 75也 percentile of the ST2,6Gal I activity of the 
non-tumor and tumor tissues from HCC patients in the msAFP unchanged and 
msAFP increased groups. Eleven patients with msAFP % lower than 19.0 % were 
categorized as msAFP unchanged and 8 patients with msAFP % higher than 19.0 % 
were classified as msAFP increased. 
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P 二 0.302 * P = 0.035 
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FIGURE 15 - Comparison of the median ST2,6Gal I activities in 
non-tumor and tumor tissues between the msAFP unchanged and 
increased groups. Solid box represents the ST2,6Gal I activity in 
the msAFP unchanged group and open box represents the ST2,6Gal 
T activity in the msAFP increased group. A significant decrease was 
observed in the tumor tissue of the msAFP increased group 
comparing to that of the msAFP unchanged group (P = 0.035). The 
difference in ST2,6Gal I activity in non-tumor tissue between the 
two groups was not significant (P = 0.302). (Wilcoxon Signed Rank 
Test). 
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* P 二 0.042 0.039 
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(n = l l ) (n = 8) 
FIGURE 16 -Comparison of the median ST2,6Gal I activities 
between the non-tumor and tumor tissues in the msAFP 
unchanged and increased groups. Solid box represents the 
ST2,6Gal I activity in non-tumor tissue and open box represents 
the ST2,6Gai I 
activity in tumor tissue, A significant increase 
was observed in the ST2,6Gal I activity of the tumor tissue in the 
msAFP unchanged group (P 二 0.042). In contrast, a significant 
decrease was observed in enzyme activity of the tumor tissue in 
the msAFP increased group (P = 0.039). (Wilcoxon Signed Rank 
Test) 
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Test) (Figure 16). All the results and statistically analyses are summarized in 
Figure 17. 
2.3.3.3 Percentage Change in the ST2,6Gal I Activities in Non-Tumor and 
Tumor Tissues 
As the basal ST2,6Gal I activity in non-tumor tissue varies In different individuals, 
the percentage change in ST2’6Ga丨 I activities of the paired non-tumor and 
tumor tissues in individual patient was further analysed. The median percentage 
change of ST2，6Gal I activity in the msAFP increased group was -31.3 %, 
indicating a decrease in enzyme activity. In the msAFP unchanged group was 
51.8 %, indicating an increase in enzyme activity (Table VII). Comparison 
between the two sets of data showed a significant lower in the percentage 
change of the ST2，6Gal I activities in the msAFP increased group than that in 
the unchanged group (P = 0.006’ Mann-Whitney Rank Sum Test). 
2.3.4 Evaluation of the RT-PCR ELISA for Semi-Quantitation of ST2，6Gal i 
mRNA levels 
2.3,4.1 Evaluation of the Quality of RNA Extracted from Tissue 
To investigate if the ST2,6Gal I activity is regulated at the mRNA level, RNA 
was extracted from the liver tissue and analysed. Total RNA extracted from the 
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FIGURE 17 — Summary for the comparisons of the ST2,6Gal I activities between 
the non-tumor and tumor tissues and between the msAFP unchanged and increased 
groups. In the figure, “N-ST: represents the ST2,6Gal I activity of the non-tumor 
tissue; “T-ST，，represents the ST2,6Gal I activity of the tumor tissue; “N.S,” stands 
for not significant The figure shows that in the msAFP increased group, the 
ST2,6Gal 1 activity of the tumor tissue is decreased (P = 0.039) while in the msAFP 
unchanged group, the enzyme activity of the tumor tissue is increased (P == 0.042). 
Moreover, comparison of the ST2,6Gal I activity in the tumor tissue between the 
two groups reviews a significant decrease in the msAFP increased group (P = 
0.035). No significant difference was found between the enzyme activities of the 
non-tumor tissues between the two groups (P = 0.302) 
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Group Percentage Change of ST2,6Gal I Activity ( % ) ~ 
Median 75伪 percentile)  
msAFP Unchanged (n =11) 51.8 (37 6, 91 4) 
msAFP Increased (n =8) -31.3 (-66.0, -3.8) 
TABLE VII — The median, 25^' and 75^ percentile of the percentage change of 
ST2,6Gal I activity in the msAFP unchanged and increased groups. The percentage 
change of the enzyme activity was calculated as (T-ST — N-ST) / N-ST * 100 %, 
whereas "T-ST" represents the ST2,6Gal I activity in tumor tissue and “N-ST” 
represents the ST2,6Gal 1 activity in non-tiimor tissue. 
7 7 
were shown in figure 18. In the Figure, two ribosomal RNA bands, 28s and 18s, 
were shown demonstrating the good quality of RNA preparation. 
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RNA extracted from tissue samples 
T NT T NT T NT T ' 
4.99 k b — < ~ 28 S 
2.60 k b - ^ ^ 18 S 
FIGURE 18 - Gel electrophoresis for RNA. extracted from 
liver tissue obtained from patients histologically confirmed 
with HCC. "NT" represents the non-tumor tissue sample and 
“T” represents the tumor tissue sample. RNA was extracted 
from the tissue sample using the RNeasy Kit Electrophoresis 
was performed on a 1.25 % SeaKem® Gold agarose gel.The 
RNA bands were visualized using ethidium bromide. Three 
nanograms of RNA was loaded in each lane. The relative 
positions of 28S and 18S ribosomal RNAs are indicated 
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2.3.4.2 PCR Amplifications of the ST2，6Gaf I cDNA and fi-actin cDNA 
As shown by agarose gel analysis, ail PCR amplications with and without DIG-
labeled deoxynucleotide, including the positive control (normal human liver 
cDNA as template), produced a single band of the expected size (Figure 19), 
suggesting the PCR amplifications are highly specific. 
2.3.4.3 Confirmation of the Specificities of the Probes for PCR-ELISA 
To test the specificities of the probes, irrelevant probes were used for 
hybridization to serve as negative controls. Results demonstrate that signal was 
only observed In hybridization where appropriate probes were used (raw data 
not shown) and thus showing the probes were specific for using in PCR-ELISA. 
2.3.4.4 Evaluation of the Reliability of PCR-ELISA 
The good fitting of the standard curves for both ST2’6Gal I (Figure 20) and p-
actin (Figure 21) has demonstrated the quantitative nature of the assay. The 
coefficient of variations of the assays were 10.5 % (ST2’6Gal 丨 assay) and 9.8 
% (p-actin assay). Therefore both assays are reliable tools to semi-quantify the 
mRNA levels. 
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FIGURE 19 — Electrophoresis for PGR products of tissue 
samples. The templates used were cDNAs reverse-transcribed 
from RNA extracted from tissue samples. “NT, represents non-
tumor tissue sample and “T” represents tumor tissue sample. 
The ST2,6Gal I cDNA and p-Actin cDNA were amplified 
separately using the appropriate primers as detailed in Methods. 
The lanes labeled with “DIG-labeled，’ were PGR products 
amplified with DIG-dNTP. The positive control was 
commercially available normal human liver cDNA. The 
negative control was PCR reaction without template. The 
expected sizes of the PCR products for ST2,6Gal I DNA and p-
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FIGURE 20 • Standard curve for PCR-ELISA in 
amplification of ST2,6Gal I cDNA. One of the tissue sample 
was used as the calibrator. A 25-fold dilution of the reverse 
transcription product of the calibrator was assigned as 1 
arbitrary unit of the mRNA concentration. 
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FIGURE 21 - Standard curve for PCR-ELISA in 
amplification of P-actin cDNA. One of the tissue sample 
was used as the calibrator. A 25»fold dilution of the 
reverse transcription product of the calibrator was 
assigned as 1 arbitrary unit of the mRNA concentration. 
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2.3.5 Semi-Quantitation and Comparisons of ST2,6Gal I mRNA 
levels in the non-Tumor and Tumor Tissues 
2.3.5.1 ST2,6Gal I mRNA Values in Tumor and Non-Tumor Tissue 
The relative ST2,6Gal I and the corresponding p-actin mRNA levels were semi-
quantified with reference to the calibrators. The ST2，6Gal I mRNA value was 
expressed as the ratio of ST2’6Gal I mRNA 丨evel/p-actin mRNA level. In some 
cases, the tissue mass was too small for RNA extraction, hence, those cases 
were omitted for mRNA semi-qunatitation.The median S丁2’6Gal 丨 mF^NA values 
of non-tumor and tumor tissue were 2.6 and 1.0 respectively (Table VIII). The 
ST2,6Ga! I mRNA values of the two groups were not significantly different (P = 
0.204, Wilcoxon Signed Rank Test) (Figure 22). 
2.3.5.2 Comparison of the ST2,6Gdl I mRNA Values Between the msAFP 
Increased and Unchanged Groups 
The data were analysed again by categorizing the cases into msAFP increased 
and unchanged groups as done before. Comparisons between the msAFP 
increased and unchanged groups showed no significant difference in both non-
tumor (P = 0.232) and tumor (P = 0.149) tissues (Mann-Whitney Rank Sum 
Test). 
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Tissue ST2,6Gal 1 mRNA Value 
Median (25'\ percentile) 
Non-tumor (11=15) 2.6 (1.8,3.4) 
Tumor (n = 12) 1.0 (0.7，2.2) 
TABLE VIII — The median, 25也 and 75也 percentile of the ST2,6Gal I mRNA value in 
paired non-tumor and tumor tissue from patients histologically confirmed with HCC. 
The ST2,6Gal I mRNA levels in the tissues were semi-quantitated by RT-PCR ELISA as 
mentioned in Methods, p-actin mRNA was used for normalization. The ST2,6Gal I 
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FIGURE 22 - Scatter plot showing the ST2，6Gal I mRNA values in 
non-tumor and tumor tissues. The ST2,6Gal I mRNA levels in the 
tissues were semi-quantitated by RT-PCR ELISA as mentioned in 
Methods, p-actin mRNA was used for normalization. The ST2,6Gal I 
mRNA value was expressed as the ratio of ST2,6Gal I mRNA level/p-
actin mRNA level. Comparison of the ST2,6Gal ！ mRNA values 
between the two groups showed no significant difference (P = 0.204, 
Wilcoxon Signed Rank Test). 
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2.3.5.3 Comparison of the ST2，6Gal I mRNA Values between tumor and 
non-tumor tissues in the msAFP Increased and Unchanged Groups 
No significant difference was found between the ST2,6Gal I mRNA values of the 
non-tumor and tumor tissue (Table IX) in both the msAFP increased (P = 0.078) 
and msAFP unchanged (P = 1.000) groups (Wllxocon Signed Rank Test). 
These findings suggest that there is no alteration of S丁2,6Gal 丨 gene 
transcription upon the development of HCC-
2.3.5.4 Percentage Change in the ST2,6Gal I mRNA Values in Non-
Tumor and Tumor Tissues 
The percentage changes in mRNA value in each pair of tissues were anaylsed. 
The results of the percentage change in ST2,6Gal I mRNA levels are shown in 
Table X. Although the sample numbers In the two groups were too small to 
allow statistical analysis, the overlapping of the groups of data suggested the 
percentage changes in the mRNA levels between the groups were not 
significantly different (Figure 23). 
2.3.6 Correlations Between the Markers 
2.3.6.1 Correlation Between the Serum AFP Level and the msAFP 
Percentage 
To evaluate if the presence of msAFP was caused by increased production of 
AFP molecules, the correlation between the serum AFP concentration and the 
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ST2,6Gal I mRNA Value 
Median percentile)  
Tissue msAFP Unchanged Group msAFP Increased Group 
Non-Tumor 3,1(2.0,4.4) 3.1 (2.0,4.4) 
( n ^ (11 = 7) 
Tumor 0 J (0.6, 1.7) 0.7 (0,6, 1.7) 
(n 二 5) (n = 7) 
TABLE IX — The median, mid 75也 percentile of the ST2，6Gal I activity of the iion-
tumor and tumor tissue from HCC patients in the msAFP unchanged and msAFP 
increased groups. Patients with msAFP % lower than 19.0 % were categorized into the 
msAFP unchanged group and those with msAFP % higher than 19.0 % were classified 
into the msAFP increased group. The ST2,6Gal I mRNA levels in the tissues were semi-
quantitated by RT-PCR ELISA as mentioned in Methods, p-actin mRNA was used for 
normalization. The ST2，6Gal I luRNA value was expressed as the ratio of ST2，6Gal I 
inRNA level / p-actin inRNA level. 
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Group Case Percentage Change of 
ST2，6Gal I mRNA Value 
m  





msAFP Increased 1 -91.6 






TABLE IX - The percentage change of ST2,6Gal I mRNA value in the msAFP 
unchanged and increased groups. The percentage change of the enzyme activity 
was calculated as (T-ST mRNA — N-ST mRNA) / N-ST mRNA » 100 %. 
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FIGURE 23 - Scatter plot showing the percentage changes of 
ST2,6Gal I mRNA value in the msAFP unchanged and increased 
groups. 
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msAFP percentage was Investigated. A strong positive correlation was found 
(Figure 24) (r = 0.612, P = 0.005, Spearman Rank Order Correlation Test). 
2.3.6.2 Correlation Between the Percentage Change in ST2,6Gal I Activity 
and the Percentage ofmsAFP 
Previous results have shown that in ST2,6Gal f activity in tumor tissue when 
msAFP percentages was increased. To further investigate the relationship 
between the two parameters, correlation was examined between the percentage 
change of ST2,6Gal I activities in the paired tissues and the AFP banding 
patterns. A strong negative correlation between the percentage change of 
ST2,6Gal I activities and the presence of msAFP percentage was found (Figure 
25) (r =-0.540, P = 0.0168). 
2.3.6.3 Correlation Between the ST2，6Gal / Activities and the Percentage 
OfmsAFP 
In evaluation of the relationship between the absolute ST2,6Gal ！ activity in 
tumor tissue and the msAFP percentage, a negative association appeared to be 
present (Figure 26) (r = -0.423，P = 0.0698), of which the p-value was just a bit 
higher than 0.05. 
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FIGURE 24 — The relation between the percentage of msAFP in 
serum and the serum AFP concentration. Analysis of the data 
showed a positive correlation (r = 0.612, P = 0.005, n 二 19, 
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FIGURE 25 一 The relation between the percentage change in 
ST2，6Gai I activity and the percentage of msAFP in serum. 
Analysis of the data showed a negative correlation (r = -0.540, P 
=0.0168, n = 19，Spearman Rank Order Correlation test). 
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FIGURE 26 - The relation between the ST2,6Gai I activity 
in tumor tissue and the percentage of msAFP present in 
serum. Analysis of the data showed a negative correlation (r 
二 -0.423, P = 0.0698, n = 19, Spearman Rank Order 
Correiation test). 
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2.3.6.4 Correlation Between the ST2,6Gal I mRNA Value and the 
ST2,6Gdl I Activity 
Since the enzyme activity is possible to be regulated at translational / post-
translational level which in turn is regulated by the transcriptional level, the 
correlation between ST2,6Gal I mRNA value and the ST2,6Gal I activity was 
examined. The results showed that the mRNA levels are positively correlated 
with the ST2,6Gal I activities in non-tumor tissue (Figure 27) (r 二 0.643 P = 
0.009). However, no significant correlation was found between the ST2,6Gal { 
mRNA levels and the enzyme activity in tumor tissue (Figure 28) (r =0.308, P = 
0.317). 
2.3.6.5 Correlation Between the Percentage Change in ST2，6Gal I mRNA 
Value and the Percentage Change in ST2,6Gal I Activity 
Analysis of the percentage change of ST2,6Gal I mRNA value and the 
percentage change of ST2,6Gal I activity revealed no significant correlation 
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FIGURE 27 - The relation between the ST2,6Gal I mRNA 
value and the ST2,6Gal I activity in non-tumor tissue. 
Analysis of the data showed a positively correlation (r 二 
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FIGURE 28 - The relation between the ST2,6Gal I luRNA 
value and the ST2,6Gal I activity in the tumor tissue. 
Analysis of the data showed no significant correlation (r 二 
0.308, P = 0.317, n = 12，Spearman Rank Order Correlation 
test). 
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FIGURE 29 - The relation between the percentage 
change of ST2,6Gal I activity and the percentage 
change of ST2,6Gal I mRNA value Analysis of the 
data showed no significant correlation (r = 0.483, n = 
0.105，n 二 12，Spearman Rank Order Correlation test). 
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2.4 Discussion 
2.4.1 Overproduction of AFP, a Possible Cause for Increased msAFP 
Formation 
A positive correlation was found between the serum AFP concentration and the 
msAFP percentage In the HCC patients. This indicates that when the serum 
AFP concentration was higher, the percentage of msAFP in serum was also 
higher. Asialo-AFP is the precusor of dsAFP and msAFP is the intermediate 
products before fully siaiyiated. As all the patients involved in this study had 
serum AFP levels above the normal reference range (I.e. < 1 0 ng/ml), the 
presence of msAFP in HCC might be due to the increased production of asiab-
AFP. The increase in asialo-AFP production would lead to saturation of 
ST2，6Gal I enzyme and / or sialic acid, which in turn might lead to a failure In full 
sialylation (dsAFP) of all AFP protein molecules. Finally, some hyposialylated 
AFP (msAFP) might be then secreted to the blood stream. 
However, the data showed that in some patients whose serum AFP levels were 
less than 100 ng/ml, the percentage of Band +!l AFP was higher than 19%. On 
the other hand, In some patients with serum AFP concentration higher than 500 
ng/ml, the percentage of Band +11 AFP was lower than 10 %. Furthermore, the 
serum AFP levels between the msAFP increased and unchanged groups were 
not significantly different. These observations imply that, apart from the 
saturation of ST2,6Gai 1, other physiological change(s) should be involved 
accounting for the formation of msAFP in HCC. 
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2.4.2 Decrease of ST2，Ga! I Activity, a Possible Cause for Increased msAFP 
Formation 
Apart from the Increase in AFP production, decrease in the activity of ST2,6Gal 
I is also a possible mechanism contributing to the formation of msAFP. As 
asialo-AFP is the precusor of the fully sialylated AFP, decrease in ST2’6Gal I 
activity may lead to the hyposialyiation of AFP molecules, and hence, msAFP is 
formed. In evaluation of this hypothesis, the activities of S丁2,6Ga丨 I in non-tumor 
and tumor tissues were measured and compared. 
in the msAFP increased group, the activity of ST2,6Gal I was found to be 
lowered in the tumor tissue when comparing to the non-tumor tissue. Moreover, 
comparisons of both the absolute activities and the percentage changes of 
ST2,6Ga! I in tumor tissues between the msAFP increased and unchanged 
groups also showed a significant lower enzyme activity in the msAFP increased 
group. Such findings strongly support our hypothesis that increase production of 
msAFP by HCC is due to the decrease in the intracellular ST2,6Ga! ！ activity. 
This is further supported by observation that the ST2,6Gal I activities in the non-
tumor tissues between the msAFP increased and unchanged groups were not 
significantly different 
On the contrary, the activity of ST2,6Gai I was found to be increased in the 
tumor tissue when comparing to that in the non-tumor tissue in the msAFP 
unchanged group. Such big difference between the msAFP increased group 
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and the unchanged group may explain why there was no significant difference in 
the ST2,6Gal I activities between the tumor and non-tumor tissues when al! 
cases were subjected to data analysis. Probably the pathophysiology of the 
tumors with increased production of msAFP is different from those without 
significant Increase production of msAFP, especially in terms of post-
translational modification of glycoproteins. 
To further elaborate on our suggestion that decrease in ST2,6Gal ! activity is 
associated with the increase in msAFP, the ST2,6Gal I activity and the 
percentage of msAFP were subjected to correlation analysis. Since the n 
numbers for both the msAFP increased and unchanged groups were small, on 
all the patient data were used in correlation analysis. 
A strong negative correlation was found between the percentage change of the 
ST2，6Gal I activity and the percentage of msAFP. This again supports our 
hypothesis that the decrease in ST2，6Gal I activity in tumor tissue results in an 
increase in the msAFP percentage in serum. Consistent with this result, 
examination of the relationship between the absolute ST2，6Gal I activity and the 
percentage of msAFP appeared to be negatively correlated. Since the basal 
absolute ST2,6Gal I activities vary in different individuals, the absolute ST2,6Gal 
I activity in tumor tissue may not be a good marker to indicate the relationship, 
hence leads to a p-value slightly greater than 0.05. 
Among the patients, only patient no. 4 was found to have msAFP absent in the 
serum. Regarding this patient, although the ST2，6Gal I activity measured in the 
tumor tissue was not exceptionally high, it was found to have increased for 50% 
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comparing to the non-tumor tissue. Moreover, the serum AFP concentration of 
the patient was low (i.e. 69 ng/ml). Therefore, it was likely that the msAFP 
percentage would not have increased. Although msAFP was found to be highly 
specific for HCC patients, not all HCC patients, like patient no, 4 in this study, 
have circulating hyposialylated AFP. It is likely that in patients with msAFP 
unchanged, the presence of msAFP is regulated by factors other than the 
concentration of AFP and ST2,6Gal 1 activity. 
ST2，6Gal I Activity in Tumor is not Regulated at Transcriptional Level 
To Investigate if the changes in ST2,6Gal I activities was regulated at the 
transcriptional level, correlations between the S丁2,6Gal 丨 activity and the mRNA 
level were examined. In the tumor tissue, no significant correlation was found 
between the enzyme activity and mRNA value. This suggests that the ST2,6Gal 
1 activity in HCC is not regulated at the transcriptionai level. This implication was 
also supported by the result that no significant correlation was found between 
the percentage change of the ST2,6Ga! I activity and the percentage change of 
the ST2，6Gal 1 mRNA value. 
In contrast, the ST2,6Gal I activity was found to be positively correlated with the 
ST2，6Gal 1 mRNA value in the non-tumor tissue. This suggests that in normal 
tissue the enzyme activity is regulated at the transcriptional level. Similar finding 
was reported by Svensson et al. They have shown that high ST2，6Gal 丨 activity 
in norma丨 liver is due to the high expression of the ST2，6Gal I gene under the 
regulation of liver restricted transcription factors, like HNF-1 and DBP^^ .^ 
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Genersil Discussion 
Origin of blood msAFP 
it has been demonstrated in several studies in human''^ ®'''^ '^  that a major source 
of blood AFP in adult is derived from the hepatocellular carcinoma. The 
presence of msAFP, in addition to dsAFP, in the sera of HCC patients can be 
due to either incomplete siaiyiation of the AFP, or due to conversion of dsAFP to 
msAFP by sialidase / glycosidase digestion after the fully sialylated molecule 
has been synthesized and released to the blood stream. Investigation of the 
AFP isoforms in the culture medium using Hep G2 cell line showed that the 
percentage of msAFP in the short-term culture was not increased with time 
during prolonged incubation at 37 This suggests that formation of msAFP 
molecules is not a consequence by extracellular conversion of dsAFP to msAFP. 
Hence, the msAFP detected in the culture medium must be formed inside the 
tumor cells, and secreted out from the cells. In accordance with this finding, we 
suggest that the degree of siaiyiation of circulating AFP is a process governed 
by a cellular mechanism Inside the HCC cells and hence, serological AFP 
isoforms are reliable markers, reflecting those produced by HCC. However, 
further evaluation of our suggestion should be made by investigating the 
presence of sialidase I glycosidase in human serum as described in the 
discussion section in Chapter 2. 
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Physiological Mechanism for the formation of msAFP in HCC 
The findings of the project indicate that there are at least two causes for the 
formation of msAFP in HCC. Firstly the positive correlation between the serum 
total AFP concentration and the msAFP percentage suggest that over-
production of AFP molecules may saturate the intracellular ST2,6Gai I enzyme, 
leading to the formation of the incomplete sialylated form. Secondly the 
formation of msAFP may be due to the decrease of intracellular ST2,6GaI 1 
activities, which is responsible for sialylation of AFP molecules in normal liver. 
Besides the increased production of AFP, the presence of at least one more 
cause for the formation of msAFP helps to explain why high AFP levels are not 
necessarily associated with high percentage of msAFP. On one hand, it is 
observed in our data that some cases with high AFP levels has low percentage 
of msAFP. On the other hand, some cases with AFP level similar to the liver 
cirrhosis cases has high percentage of msAFP. 
Consistent with our results which showed that ST2，6Ga! I activity was correlated 
to the degree of sialylation, study conducted by Ernst F et a! on fetal mouse 
AFP has demonstrated that the increase in sialyltransferase activity in liver 
tissue correlates well with the increased sialylation of AFP''^" Furthermore, in 
another study on transformed normal 3丁3 mouse fibroblast ceils, it has been 
suggested that decrease in sialyltransferase was responsible for the decreased 
sialylation in the transformed cells'''"®. 
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In a study using transgenic mouse model, ST2，6Gal I activity was found to 
increase in the HCC^^ .^ Unfortunately the degree of the sialylation of the AFP 
molecules produced by the tumor was not investigated in the study. In the 
present study, we also found an increase in the ST2，6Gal I activity in the HCC 
patient group without significant increase of serum msAFP. It appears that HCC 
can be least divided into two subtypes, one with decreased tumor ST2,6Gal I 
activity and increased production of msAFP, and one with increased tumor 
ST2,6Gal 1 activity and without significant production of msAFP. Further studies 
are necessary for investigating the differences in the biological properties 
between these two HCC subtypes. 
Regulation of ST2,6Gal I Activity in HCC 
Consistent with most studies regarding the regulation of the activity of 
ST2,6Gal I, the ST2，6Gal I activity in the non-tumor tissue was found to be 
closely correlated to the mRNA level, suggesting the enzyme activity is 
regulated at the transcriptional level. However, no significant correlation was 
found between the mRNA levels and the ST2，6Ga丨丨 activity in the tumor. 
Furthermore, in tumor tissue, the percentage change of the ST2,6Gal 丨 activity 
was not significantly correlated with the percentage change of the ST2,6Gal I 
mRNA level. These findings strongly suggest that the S丁2，6Gal I in tumor tissue 
is not regulated at the transcriptional level. Since the microsomal fraction was 
used in the experiment when measuring the ST2，6Gal 丨 activity，it is not likely 
that the decrease in enzyme activity is due to the presence of inhibitors in the 
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cytosol. Hence, the decrease in ST2,6Gal I activity in HCC should be due to 
change in enzyme function. The change in enzyme function may be caused by 
mutation, deletion, alternate splicing or post-translational modificatiorL 
It has been found that liver expresses two isoforms of ST2,6Gal I RNA differing 
by a single nucleotide. The ST cys possesses a tyr at amino acid 123 and the 
ST tyr possesses a tyr at the same position. Both types of enzyme are shown to 
be active in tissue culture. However, the more stable ST cys is retained intact in 
cells while the unstable ST tyr is rapidly cleaved and secreted''^. It is possible 
that there are two subtypes of tumor tissues which express different isoforms of 
ST2,6Gal 1, leading to the difference in their ST2，6Gal I enzyme activities. The 
HCC patients without increase of serum msAFP may preferentially up-regulate 
the expression of the stable ST cys isoform and hence, the enzyme activity was 
found to be increased, whereas, the HCC patients with increase of serum 
msAFP may preferentially express the unstable ST tyr isoform leading to the 
decrease in enzyme activity. 
Another possibility is some HCC expresses alternately spliced ST2,6Gal I 
mRNA, which encodes for inactive truncated ST2,6Gal ！ isoform. It has been 
found that the alternate splicing of ST2,6Gal I mRNA occurs at the 5' terminal of 
the mRNA leading to the formation of different isoforms'^Since our semi-
quantitative ST2,6Gai \ mRNA assay detects the region of ST2,6Gal i mRNA 
locating dose to the 3，end of the transcript, both normal and alternate spliced 
forms may be detected. In addition, deletion or mutation at the 5' region of the 
mRNA, which cannot be detected in our assay, may also cause the formation of 
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the inactive form of enzyme leading to the decrease in ST2,5Gal I activity of the 
tumor tissue in the patients with increase of serum msAFP. 
Comparison between the ST2,6Gal I activities in human HCC and Colon 
Cancer 
Although the ST2，6Gal 丨 activity in human HCC has not been reported, the 
ST2，6Gal 丨 activity in of human colon cancer has also been studied extensively. 
It has been found that the enzyme activity is increased markedly in colon 
canceri24’i25 instead of decreased in liver cancer as suggested in our study. 
Such difference could be explained by several possible reasons. Firstly, it has 
been suggested that the enhanced ST2,6Ga丨丨 activity is characteristic for 
metastasizing tumors”2,i26-i28 Metastasis of colon cancer cells is mostly 
circulated to the host liver''^ ®. However, liver cancer cells do not need to 
metastasis to liver itself. Moreover, as the basal level of the ST2,6Gal I activity 
in normal colon tissue is low, the only possible direction of deregulation of the 
enzyme is to increase the activity. In contrast, the basal ST2’6Gal 丨 activity in 
liver tissue is particularly high, therefore, deregulation of the enzyme can be 
either in ways increasing or decreasing in the activity. 
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Conclusion 
The present study suggests that in hepatoma cells, msAFP is formed inside the 
HCC cells before secreted out of the cells. Regarding the formation of msAFP, a 
positive correlation was found between the percentage of serum msAFP and the 
total serum AFP level. This suggests that over production of asialo-AFP, which 
leads to the saturation of ST2，6Gal I, may be one of the factors causing the 
formation of hyposialylated AFP. Moreover, the presence of serum msAFP was 
associated with decreased ST2,6Gal i activity in the HCC tumor. Furthermore, 
the tumor ST2,6Gal I activity was negatively correlated with the serum msAFP 
percentage. The findings of this study suggest that the formation of msAFP is 
also a consequence of the decrease in ST2,6Gal I activity in the HCC cells. This 
change of enzyme activity in HCC is not regulated at the transcriptional level, 
hence, gene mutation, gene deletion, alternate splicing or posMranslationa! 
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